



MECHANISM OF A NATURAL PRENYLFLAVONOID, 
ICARITIN, AS AN ANTI-OSTEOCLAST AGENT FOR 
POSTMENOPAUSAL OSTEOPOROSIS: 
CELLULAR AND ANIMAL STUDIES 
 
TAN EE MIN 
B.SC. (HONS.), QUEEN MARY UNIVERSITY OF LONDON 
 
A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
DEPARTMENT OF MEDICINE 





PROF YONG EU LEONG 
DR NICHOLAS CHEW 
EXAMINED BY: 
ASSOCIATE PROFESSOR CHRISTOPH WINKLER 
ASSISTANT PROFESSOR TOH WEI SEONG 





I hereby declare that this thesis is my original work and it has been written by 
me in its entirety. I have duly acknowledged all the sources of information 
which have been used in the thesis. 





Tan Ee Min 
1 January 2017 
 
 ACKNOWLEDGEMENTS 
I thank my lucky stars for the people who have made this journey possible: 
 
To my supervisor Prof Yong Eu Leong, and my co-supervisor Dr. Nicholas Chew, 
who have been guiding my research and without whom there would have been 
nothing much to write in this thesis. Thank you for giving me this tremendous 
learning opportunity, for your advice and guidance. 
To Dr Li Lei and Dr inthrani Raja Indran, who selflessly took on the role as my 
mentors. Thank you for generously sharing your knowledge with me, for your 
guidance in developing ideas and when experiments go wrong. I thoroughly 
enjoy the mini- seminar sessions we hold in the corridors of the lab, in the office 
pantry and am grateful for the critique you’ve given me on my work. Thank you 
for your encouragements when I needed them most. And not forgetting Dr. 
Inthrani’s subtly pushing me to work harder by implementing lab meetings; you 
were right, we just had to set presentation dates and I’d have to figure the rest 
out in time.  
To my lab mates Ryan, Audrey, Bao Hui, Helen and Zhi Wei, thank you for 
helping me out when my experimental schedule was too packed, when I needed 
extra pairs of hands in the animal facility, and for sharing your “contacts” with 
me when I sourced for reagents or equipment. Thank you for the emotional 
support you’ve given me, for stocking up pantry snacks, for making me laugh. I 
couldn’t have asked for better companionship these years. And a special mention 




even though it’s beyond their job scope. Not forgetting the endless supply of 
coffee Helen has provided me with. 
And of course, to my parents who have been nothing but patient and tolerant 
with me, thank you for this Workaholic gene that I’ve inherited from you both; I 
could not have completed this PhD candidature without it. I know that jumping 
into this PhD is perhaps a decision you may never fully comprehend, but thank 
you for asking me repeatedly over the years what it is I’m working on; even if you 
don’t understand or remember, at least you keep asking. Thank you for the space 
you’ve given me; I know I haven’t given you much choice but to grow accustomed 
to my returning to the lab in the middle of the night for the odd time points, and 
on weekends. And of course, thank you for all the love and support you have 
showered me. 
 TABLE OF CONTENTS 
Summary i 
List of tables ................................................................................................................... iii 
List of figures ..................................................................................................................iv 
List of abbreviations ....................................................................................................vi 
List of publications .................................................................................................... viii 
CHAPTER 1. INTRODUCTION ...................................................................................... 1 
1.1  Osteoporosis ......................................................................................................... 1 
1.1.1 Postmenopausal osteoporosis: epidemiology and financial burden ................ 3 
1.1.2 Postmenopausal osteoporosis in Singapore ............................................................... 5 
1.1.3 Screening and diagnosis of postmenopausal osteoporosis .................................. 6 
1.1.4 Fracture risk assessment .................................................................................................... 8 
1.1.5 Treatment modalities of postmenopausal osteoporosis ....................................... 9 
1.1.5 Estrogen deficiency-mediated osteoporosis ............................................................. 19 
1.1.6 Flavonoids and osteoporosis ........................................................................................... 21 
1.2 Bone metabolism .............................................................................................. 24 
1.2.1 Macroscopic organization of bone ................................................................................ 24 
1.2.2 Bone remodeling .................................................................................................................. 27 
1.2.3 Bone cells ................................................................................................................................. 30 
1.3 Osteoclastogenesis and the RANKL/RANK signaling pathway ......... 35 
1.3.1 Importance of TRAF6 in RANK signaling ................................................................... 37 
1.3.2 NFκB signaling cascade in osteoclast differentiation ............................................ 38 
1.3.3 MAPK/AP-1 signaling cascade in osteoclast differentiation .............................. 39 
1.3.4 Intracellular ROS in osteoclast differentiation......................................................... 40 
1.3.5 Role of NFATc1 in osteoclast differentiation ............................................................ 41 
1.4 Epimedium (Berberidaceae) for bone health ........................................ 43 
1.4.1 Chemical constituents of the genus Epimedium ...................................................... 43 
1.4.2 Effects of icaritin on bone ................................................................................................. 45 
1.4.3 Dietary source of icaritin................................................................................................... 46 




1.5.1 Osteoclast-generating cocultures .................................................................................. 47 
1.5.2 Osteoclast precursors ......................................................................................................... 48 
1.6 The ovariectomized rat model ..................................................................... 51 
1.6.1 Shortcomings of the OVX rat model.............................................................................. 53 
CHAPTER 2. AIMS ........................................................................................................ 54 
2.1.1 Knowledge gaps .................................................................................................................... 54 
2.1.2 Hypothesis and specific aims .......................................................................................... 55 
CHAPTER 3. MATERIALS & METHODS ................................................................. 57 
3.1 Cellular experiments ....................................................................................... 57 
3.1.1  Chemicals ................................................................................................................................ 57 
3.1.2  Cell Culture ............................................................................................................................ 57 
3.1.3  Osteoclastogenesis Assay ................................................................................................ 58 
3.1.4  Osteoclast Function ............................................................................................................ 59 
3.1.5  Real-time Polymerase Chain Reaction ....................................................................... 62 
3.1.6  Immunoprecipitation (IP) ............................................................................................... 63 
3.1.7  Cell fractionation ................................................................................................................. 63 
3.1.8  GTP-bound Rac1 Isolation ............................................................................................... 64 
3.1.9  Protein extraction & immunoblot analyses .............................................................. 65 
3.1.10 Cell viability assay ............................................................................................................... 67 
3.1.11 Immunofluorescence analysis ........................................................................................ 67 
3.1.12 Intracellular ROS detection ............................................................................................. 68 
3.1.13 Assessment of NFATc1, NFκB and AP-1 transcriptional activities ................. 69 
3.1.14 Calcineurin-specific phosphatase assay ..................................................................... 72 
3.1.15 Statistical analyses .............................................................................................................. 73 
3.2 Animal Experiments ........................................................................................ 74 
3.2.1  Establishing the OVX-rat model .................................................................................... 74 
3.2.2  Preparation of treatments ............................................................................................... 74 
3.2.3  Vaginal smears ..................................................................................................................... 75 
3.2.4  Blood sampling and parameters ................................................................................... 77 
3.2.5  Micro-computed tomography measurements ........................................................ 77 
3.2.6  Mechanical tests .................................................................................................................. 78 
3.2.7  Identification and analysis of circulating osteoclast precursors ..................... 80 
3.2.8  Bone histology ...................................................................................................................... 83 




3.2.10  Statistical analysis .............................................................................................................. 85 
CHAPTER 4. RESULTS ................................................................................................. 86 
4.1 Effect of icaritin on osteoclastogenesis and function in vitro .............. 86 
4.1.1 Icaritin inhibited osteoclast formation ....................................................................... 87 
4.1.2 Icaritin inhibited expression of osteoclast-specific genes .................................. 89 
4.1.3 Icaritin inhibited bone resorption in RAW 264.7 cells and human PBMCs . 91 
4.1.4 Inhibitory effects of icaritin not due to non-specific cytotoxicity .................... 94 
4.1.5 Icaritin does not have effect on mature osteoclasts .............................................. 96 
4.2 Mechanism by which icaritin inhibits osteoclast differentiation .... 99 
4.2.1 Effects of icaritin not mediated via estrogen-receptor signaling ..................... 99 
4.2.2 Icaritin did not reduce RANK expression of osteoclast precursors ............. 101 
4.2.3 Icaritin inhibited RANKL-induced NFκB signaling pathway ........................... 103 
4.2.4 Icaritin inhibited RANKL-induced MAPK/AP-1 signaling pathway ............. 106 
4.2.5 Icaritin suppresses RANKL-induced intracellular ROS production ............. 108 
4.2.6 Icaritin inhibited RANKL-induced TRAF6/cSrc/PI3K signalling .................. 109 
4.2.7 Inhibition of ROS-mediated calcineurin phosphatase activity and NFATc1 
activity ................................................................................................................................................... 111 
4.2.8 Icaritin mediates proteasomal degradation of TRAF6 ...................................... 113 
4.2.9 Icaritin and TRAF6 ubiquitination ............................................................................. 115 
4.3 Effects of icaritin in the OVX rat model .................................................. 117 
4.3.1 To establish and validate the OVX-rat model ........................................................ 118 
4.3.2 Icaritin treatment prevented OVX-induced deterioration in bone 
architecture ......................................................................................................................................... 118 
4.3.3 Icaritin treatment prevented OVX-induced decline in bone strength ......... 123 
4.3.4 Icaritin treatment suppressed osteoclast formation and resorption in vivo
 125 
4.3.5 Icaritin treatment suppressed TRAF6 protein expression .............................. 128 
4.3.6 Icaritin treatment suppressed NFATc1 protein expression ............................ 133 
4.3.7 Icaritin treatment did not lead to changes in RANKL levels ........................... 135 
4.3.8 Icaritin treatment has favourable short-term safety profile in OVX rats ... 136 
CHAPTER 5. DISCUSSION ....................................................................................... 139 
5.1 Effects of icaritin on osteoclastogenesis ................................................ 140 




5.2 Mechanism by which icaritin inhibits osteoclast differentiation . 142 
5.2.1 Icaritin inhibited NFATc1 expression via NFκB and MAPK/AP-1 pathways
 142 
5.2.2 Icaritin inhibits NFATc1 nuclear translocation and transcriptional activity 
by suppressing the TRAF6/cSrc/Nox1 pathway ................................................................. 144 
5.2.3 Proteasomal degradation of the critical adaptor protein, TRAF6, mediates 
icaritin’s suppression of osteoclastogenesis ......................................................................... 145 
5.2.4 Comparison with other flavonoids that inhibit RANKL signaling ................. 147 
5.3 Beneficial effects of icaritin in the OVX rat model ............................. 150 
5.3.1 The OVX rat model and timing of administration of icaritin ........................... 150 
5.3.2 Preventing OVX-induced deterioration in bone architecture & strength .. 151 
5.3.3 Ameliorating OVX-induced increase in TRAF6 and NFATc1 expression ... 151 
5.3.4 Anabolic effect of ICT in osteoporotic bone ........................................................... 152 
5.4 Potential clinical applications ................................................................... 154 
5.4.1 Inflammatory diseases ........................................................................................................ 154 
5.4.2 Treatment of postmenopausal osteoporosis and future work ........................... 155 






As women approach menopause, ovarian function declines and the drastic 
decrease in estrogen levels lead to osteoporosis. Postmenopausal osteoporosis 
is characterized by a decrease in bone mineral density and strength, leading to 
a significant increase in the risk of fractures. However, current anti-
osteoporotic drugs are associated with clinical adverse events, thus there is a 
need to identify alternative treatment options with improved risk-benefit 
profiles. 
 
The findings of this thesis uncover the potential clinical utility of icaritin, a 
natural prenylflavonoid, as a therapeutic agent for postmenopausal 
osteoporosis. We show that icaritin treatment inhibited osteoclastogenesis in 
both mouse and human monocytes, and suppressed osteoclast resorption in 
these cellular models. We further delineated the mechanism(s) by which 
icaritin inhibits osteoclast differentiation, summarized in the following 
diagram: by mediating proteasomal degradation of the critical adaptor 
protein, TRAF6, icaritin inhibited downstream NFκB, MAPK/AP-1, and ROS 
signaling pathways, to suppress both NFATc1 expression and transcriptional 
activity, ultimately downregulating the expression of osteoclast-specific genes. 
These findings were corroborated in the ovariectomized (OVX) rat model.  In 
the OVX rat model, a well-established model of estrogen deficiency-mediated 
osteoporosis, icaritin treatment inhibited osteoclast formation and resorption 
thereby preventing ovariectomy-induced deterioration in bone architecture 




osteoclastogenesis by icaritin treatment was associated with decreased 
TRAF6 and NFATc1 protein expression in the circulating osteoclast precursors 
as well as in tibial lysates. We conclude that icaritin inhibits osteoclast 
differentiation from its precursors by repressing the expression of the TRAF6 
adaptor protein, an effect that was consistently observed both in vitro and in 
vivo. 
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CHAPTER 1. INTRODUCTION 
1.1  Osteoporosis 
Osteoporosis or “porous bones” is a highly prevalent condition characterized 
by decreased bone mass and density that occurs when undue amounts of 
protein and minerals are lost from skeletal tissue. This loss in bone mass is 
accompanied by structural changes that lead to increased brittleness and a 
decrease in the strength of bones thus resulting in a significant increase in 
fracture risk (Cagnetta & Patella, 2012). As such, the morbidity and mortality 
associated with osteoporosis is secondary to the fractures that occur. Since 
bone loss occurs gradually and asymptomatically with aging, coupled with the 
demographic transitions occurring worldwide, the prevalence of osteoporosis 
is rising steadily and is projected to increase substantially (Cooper et al., 
2011). 
 
Osteoporosis is traditionally classified into primary and secondary 
osteoporosis. Type 1 primary osteoporosis affects postmenopausal women, 
while type 2, also known as senile osteoporosis affects both men and women 
above the age of 75. Several risk factors have been identified for primary 
osteoporosis as indicated in Table 1.1. Secondary osteoporosis, as its name 
suggests, is a bone disorder that results from complications of other medical 
conditions such as endocrine and metabolic disorders (for eg. 





malabsorption conditions), or due to the extended use of drugs, such as 
glucocorticoids, selective serotonin reuptake inhibitors and anticoagulants. 
 
 
Table 1.1 Major risk factors for primary osteoporosis  
Advancing age 
Female sex 
White or Asian race 
Low body weight/ body mass index 
Family history of osteoporotic fractures 
Early menopause 
Sedentary lifestyle 
Excessive alcohol (> 2 drinks per day), caffeine, and tobacco use 
Low calcium and/or Vitamin D intake 
Inadequate sun exposure 
Athletic amenorrhoea 
 






1.1.1 Postmenopausal osteoporosis: epidemiology and financial burden 
Postmenopausal osteoporosis affects more than 200 million women 
worldwide (Reginster & Burlet, 2006) and it is estimated that by the age of 80, 
70% of women will be osteoporotic at the hip, lumbar spine or forearm 
(Melton, 1995).  Indeed the high prevalence of osteoporosis is accompanied by 
a high incidence of osteoporotic fractures. It has been reported that 
approximately 9 million osteoporotic fractures occur annually worldwide 
(Kanis et al., 2000). Further, 1 in 3 women above 50 will suffer from 
osteoporotic fractures, particularly in the hip and spine (Johnell & Kanis, 
2006). The lifetime risk of suffering an osteoporotic fracture for a 50 year old 
Caucasian woman, at ~40%, is similar to that of coronary heart disease 
(Samelson et al., 2006). 
 
Mortality rates of osteoporotic fractures vary with the type of fracture. 
Mortality rate in the first year following a hip fractures has been reported to 
be as high as 20 – 24%, while Johnell et al. (2004) also reported similar 
mortality rates for clinical spine fractures. Pneumonia and chronic obstructive 
pulmonary disease are the primary causes of mortality associated with severe 
vertebral deformities (Teng et al., 2008). Although mortality risk decreases 
after the first year, mortality at 5 years was still higher than that of the general 
population of the same age (Johnell et al., 2004). In addition to the high 
mortality rates, survivors experience an overwhelming loss of function and 
independence (Schnell et al., 2010). Only 25% of hip fracture patients are able 
to return to their activities of daily living such as walking, getting out of bed, 





This loss of independence may result from both the physical inability to walk 
and fear of falling. Unfortunately, this inactivity perpetuates a vicious cycle 
worsening osteoporosis thereby increasing the risk of falling and suffering of 
new fractures (Galsworthy & Wilson, 1996). The prevalence of vertebral 
deformities in postmenopausal women is estimated at 20% while 
approximately 10% have deformities severe enough to result in chronic back 
pain, kyphosis, and height loss (Ettinger et al., 1992). Similarly, chronic back 
pain, deformity, and immobility, as a result of vertebral fractures, have a 
significant impact not only on the patients’ daily activities but also self-esteem, 
body image and mood (Fechtenbaum et al., 2005; Tosteson et al., 2001). Gold 
et al. (2009) reported that chronic pain as a result of vertebral fractures leads 
to a complex psychosocial reaction from the patient including anxiety, 
depression, and interpersonal relationship problems. 
 
In addition to the debilitating condition that osteoporotic fractures leave 
patients, osteoporotic fractures also pose a major public health problem 
worldwide due to the associated morbidity, mortality and costs. In the US, the 
average direct medical cost of managing a fracture can amount up to $ 12 000 
(Gabriel et al., 2002), however, close to three-quarters of these fractures occur 
in patients above 65 years old, thus these expenses are typically borne by 
society. Burge et al. (2007) reported that more than 2 million fractures 
occurred in the US in 2005, amounting to a direct cost of $17 billion dollars for 
fracture treatment and care. Similar trends have been reported in Europe, 
with an estimated cost of 36 billion euros for osteoporotic fractures 





care of osteoporotic fractures in the US exceeds that of breast and gynecologic 
malignancies combined (Hoerger et al., 2009). Furthermore, the cost of 
osteoporotic fractures has been predicted to double by 2050 (Borgstrom et al., 
2007; Burge et al., 2007) due to worldwide ageing demographics. 
 
1.1.2 Postmenopausal osteoporosis in Singapore 
The IOF Asian audit (2009) found that 55 000 women in Singapore above the 
age of 50 suffer from osteoporosis. The prevalence of osteoporosis is 
projected to increase rapidly as the population of Singapore is ageing, coupled 
with the increasing life expectancy from 84 years to 92 years by 2050 (World 
Population Prospects, 2008). As such, the population aged over 50 is projected 
to be 3.9 million in 2050, making up 46% of the population (World Population 
Prospects, 2008). The age-adjusted incidence of osteoporotic fractures among 
women over the age of 50 in Singapore is currently the highest in Asia and is 
approaching that observed in American Caucasians (Cooper et al., 1992). 
Indeed, hip fracture incidence rates in women have risen at least 5 fold since 
the 1960s (Koh et al., 2001). It has been reported that the mortality rate at one 
year post-fragility hip fracture is approximately 20 – 27%, with 20% of the 
survivors partially or fully dependent on a care giver and 42% experienced 
reduced mobility (Mithal & Kaur, 2012). 
 
Osteoporotic fractures also pose a significant public health cost in Singapore. 
The median hospital stay for surgical treatment of a hip fracture is 16 days, 
costing approximately 8400 USD for the immediate hospital care, while direct 





al., 2012). Given Singapore’s ageing population, the total cost of osteoporotic 
fractures, including both immediate hospital cost and indirect costs, is 
projected to rise to 145 million USD by 2050. Osteoporotic fractures therefore 
amount to a tremendous financial burden and social dependence in Singapore. 
 
1.1.3 Screening and diagnosis of postmenopausal osteoporosis 
Osteoporosis is an asymptomatic disease and bone loss often goes undetected 
until it manifests clinically as fragility fractures or symptoms associated with a 
collapsed vertebrae, such as loss of height over time, stooped posture and 
back pain. 
 
Cooper et al. (2011) recommended that all women above the age of 65 be 
screened for osteoporosis, while women below the age of 65 be screened for 
the presence of risk factors such as early menopause, anorexia, bulimia, 
smoking habit or alcohol abuse, and the chronic use of drugs associated with 
an increased risk for osteoporosis. Additionally, possible causes of secondary 
osteoporosis such as hyperthyroidism, hypercortisolism, 
hyperparathyroidism, or glucocorticoid- and immobilization-induced 
osteoporosis should also be excluded in order to establish a diagnosis of 
postmenopausal osteoporosis. There is increasing evidence to suggest that 
patients with elevated levels of bone turnover markers can be expected to 
have greater rates of bone loss if untreated (Garnero et al., 1999). However, 
due to a lack of standardization of assays that is further complicated by large 
intra- and inter-subject variability, bone turnover markers have not been 






Although a variety of techniques, such as quantitative ultrasound or 
quantitative computed tomography, are available to assess bone mineral 
content, dual-energy X-ray absorptiometry (DXA) is presently considered the 
gold standard imaging technique for the diagnosis of osteoporosis (Engelke & 
Gluer, 2006). Due to its sensitivity to the calcium content of bone, DXA has 
been shown to offer the best predictive value for fracture risk (Bernabei et al., 
2014). An estimate of fracture risk may be obtained with DXA of radium, ulna, 
spinal column or proximal femur. The widespread clinical use of DXA at the 
proximal femur and lumbar spine is attributed to the prospective studies 
(Marshall et al., 1996) that have documented a strong gradient of risk for 
fracture prediction, furthermore, the gradients of risk are higher than those 
derived using other techniques.  
 
In 1994, the World Health Organization proposed the following descriptive 
categories for the diagnosis of osteoporosis: 
1. Normal: a value for BMD that is higher than 1 standard deviation below the 
young adult female reference mean (T-score ≥ -1 SD) 
2. Osteopenia: a value for BMD more than 1 standard deviation below the 
young female adult mean, but less than 2.5 SD below this value (-1 SD > T-
score > -2.5 SD) 
3. Osteoporosis: a value for BMD 2.5 SD or more below the young female adult 
mean (T score ≤ -2.5 SD) 
 





same T-score derived from different sites and techniques yield different 
information on fracture risk. As such, the International Osteoporosis 
Foundation recommended the adoption of a reference site and for DXA 
measurements to be taken at the femoral neck (Kanis & Gluer, 2000).  
 
1.1.4 Fracture risk assessment  
To improve patient assessment, WHO developed an algorithm to calculate the 
10- year absolute fracture risk of individual patients. This FRAX tool calculates 
a patient’s risk for hip fracture and major osteoporotic fracture (in the hip, 
spine, wrist and humerus). The algorithm includes the following risk factors: 
age, prior fracture, parental history of hip fracture, low body weight or BMI, 
use of glucocorticoids, history of rheumatoid arthritis, cigarette smoking 
status, excessive alcohol intake of 3 units or more daily and secondary 
osteoporosis (Silverman & Calderon, 2010). FRAX was developed using 
baseline and follow-up data from 9 prospective population-based cohorts and 
validated in 11 (Watts et al., 2009). The FRAX tool has since been developed 
for 27 country-specific models, including Singapore. 
 
It is noteworthy that there are several assumptions inherent in the country-
specific FRAX model: 1) The relationship between BMI and mortality is 
constant across different racial and ethnic groups. 2) Many countries do not 
have adequate data on the incidence of nonvertebral fracture and vertebral 
fractures. Data on these fractures are estimated based on the incidence of hip 
fracture in US Caucasians as the reference from the NHANES, and this ratio 





there is at present no randomized controlled trial data on fracture prevention 
in patients who were selected based on FRAX.  
 
In Singapore, screening for women below the age of 65, has been 
advocated for those with a high-risk of developing osteoporosis. To 
identify women below the age of 65, who are at high risk of developing 
osteoporosis, Koh, Sedrine, et al. (2001) have developed the Osteoporosis 
Self-Assessment Tool for Asians (OSTA): where the difference between age 
and weight (in kilograms) of patients is greater than 20, or where patients 
have a fracture risk of ≥9.3% by FRAX, BMD of these women should be 
measured. Although the setting of interventional thresholds based on 
FRAX has to be compared to a validated local population standard, such 
data is not yet available and interventional thresholds adopted are as 
recommended by the National Osteoporosis Foundation (Cosman et al., 
2014): besides osteoporotic patients, pharmacologic treatment should be 
initiated for osteopenic patients with a 10- year hip fracture probability of 
≥3% or a 10-year major osteoporosis-related fracture probability ≥20% 
based on FRAX. 
 
1.1.5 Treatment modalities of postmenopausal osteoporosis 
General management 
Exercise –The skeleton, via bone remodeling, adapts to meet the mechanical 
demands placed on the skeleton. As such, it is well established that prolonged 
bed rest or immobilization, due to paralysis or casting of a limb, may lead to 





amount of weight-bearing exercise optimal for skeletal health in patients has 
not been established, studies have shown that aerobics, weight bearing and 
resistance exercises have been shown to lead to BMD improvements in the 
spine and hip (Bonaiuti et al., 2002). Prince et al. (1991) also demonstrated in 
a comparative study that exercise plus calcium supplementation or estrogen- 
progesterone replacement could slow bone loss. Although it was found in this 
study that exercise alone was less effective than exercise and calcium 
supplementation in increasing bone mass, it also resulted in less side effects. 
Nonetheless, the exercise prescription must be appropriate for the needs of 
the patient otherwise it may lead to negative consequences. The exercise 
program, whether therapeutic and recreational, should account for the 
flexibility, muscle strength, cardiovascular fitness, and gait steadiness of the 
individual. The exercise program should also include balance and lower 
extremity strength training to prevent falls and fractures. Thus exercise 
remains an integral component of both prevention and treatment of 
postmenopausal osteoporosis. 
 
Nutrition – It has been estimated that 38-54% of BMD variance can be 
modified by environmental factors such as nutrition (Krall & Dawson-Hughes, 
1993). Nutrition has a direct and indirect role in preventing osteoporosis – 
Firstly, by supporting the mineralization of bone during growth, thereby  
enhancing peak bone mass and maximizing bone strength. Secondly, by 
decreasing the rate of bone loss with ageing and thirdly, by maintaining the 





effect of disuse on the skeleton. However, there is a high prevalence of 
calcium, protein and vitamin D insufficiency in the elderly (Gennari, 2001; 
Janssen et al., 2002). Vitamin D supplements, at a daily dose of greater than 
700 IU, have been shown to reduce the risk of falling (Bischoff-Ferrari et al., 
2004). Additionally, calcium and vitamin D supplements decrease secondary 
hyperparathyroidism and reduce the risk of proximal femur fractures 
(Meunier, 1996). As such, intakes of at least 1000 mg/day of calcium, 800 IU of 
vitamin D and of 1 g/kg body weight protein is recommended for the general 
management of osteoporosis (Tang et al., 2007). 
The consumption of other nutrients has also been shown to affect skeletal 
health via indirect effects on calcium balance.  In spite of interindividual 
differences in salt sensitivity, excessive sodium intake has been shown to 
increase urinary calcium excretion thereby negatively affecting calcium 
balance. It has been shown that for every 100 mmol of sodium excreted, 
approximately 1 mmol loss of urinary calcium is observed (Massey and 
Whiting, 1996). Nonetheless, sufficient calcium intake would counteract the 
detrimental effects of urinary calcium excretion given that there could be up 
to 2-fold differences in sodium-induced calciuria with low and high calcium 
intakes (Teucher et al., 2008). 
In a 12-year follow-up study, the risk of hip fracture over each 2-year period 
was significantly increased by the consumption of ≥2.5 units of caffeine per 
day, where one cup of coffee = one unit of caffeine, and one cup of tea equals 
0.5 unit of caffeine (Kiel et al., 1990). While the association between increased 





is hypothesized that caffeine increases urinary and faecal calcium losses and 
may provoke a negative calcium balance in presence of a low calcium diet 
(Barger-Lux & Heaney, 1995). However,  it has been reported that the 
detrimental effect of caffeine can be offset by increasing calcium intake by 
40 mg calcium for every 177.5 ml serving of caffeine-containing coffee 
(Barrett-Connor et al., 1994).  Interestingly, despite the associations observed 
between caffeine consumption and bone mineral density or fracture risk, no 
controlled study has been done with decaffeinated coffee. 
There has been controversy regarding the role of protein intake and the 
development of osteoporosis. While sufficient protein intake is essential for 
the maintenance of bone homeostasis in the elderly (Rizzoli et al., 1998), 
excessive protein intake leads to metabolic increase of acid production and 
acid renal excretion, therefore increasing calcium excretion. Nevertheless, it is 
agreed that the consumption of dairy products, which are rich in calcium, 
proteins, phosphorus and potassium, is the best way to preserve the body 
calcium economy.  
Pharmacological interventions 
There are several types of anti-osteoporotic agents available that have all been 
shown to reduce the risk of vertebral fractures. The anti-fracture efficacy of 
frequently used treatments for postmenopausal osteoporosis is summarized 






Table 1.2 Anti-fracture efficacy of frequently used anti-osteoporotic treatments  
 Effect on vertebral fracture 
risk 
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Osteoporosis Women 
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fracture 
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atrial 
fibrillation 
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heart disease  



























of the jaw 
+ : effective drug 
NA: no evidence available 







Hormone replacement therapy (HRT) – Current menopausal HRT comprises of 
17β-oestradiol or conjugated equine estrogen (CEE) supplemented with 
medroxyprogesterone acetate for women with intact uterus, or unopposed 
CEE for women who have undergone hysterectomy. HRT was initially 
prescribed to manage vasomotor symptoms in women and was suggested by 
observational studies to have beneficial effects on the cardiovascular system 
and cognitive function. Although HRT was effective in increasing BMD in the 
hip and spine thereby preventing osteoporotic fractures (Lindsay et al., 2002; 
Writing Group for the PEPI, 1996), the findings by the Women’s Health 
Initiative (WHI), a randomised, placebo-controlled trial involving more than 
16,000 postmenopausal women revealed that women undergoing HRT had 
significantly increased risks in the following diseases – breast cancer, ischemic 
heart disease, thromboembolic disease, dementia and cerebral strokes. The 
study, initially planned for duration of 8.5 years, was terminated at 5.2 years 
as the risks exceeded benefits of intervention (Writing Group for the Women's 
Health Initiative, 2002).  
 
The WHI study fuelled research to identify selective estrogen receptor 
modulators (SERMs) that elicit different effects on estrogen receptors at 
different tissues. Tamoxifen, a SERM, antagonizes estrogen receptors in breast 
tissue and was initially found to inhibit breast cancer growth. However, 
tamoxifen stabilizes ERα and prolonged use may result in tamoxifen-resistant 
breast cancer (Early breast cancer trialists' collaborative group, 2005). It has 
also been suggested that tamoxifen contributes to endometrial cancer 





prevention and treatment of postmenopausal osteoporosis. While raloxifene 
therapy has been shown to lead to increases in bone mineral density in the 
lumbar spine, total hip and femoral neck (Delmas  et al., 1997), thereby 
mitigating fracture risk by 30 – 50%, raloxifene therapy is associated with a 
significant increase in the risk of venous thromboembolism and pulmonary 
embolism (Adomaityte et al., 2008). Additionally, the effects of raloxifene 
therapy on coronary events in women with established coronary heart disease 
remains controversial (Barrett-Connor et al., 2006; Collins et al., 2009).  
 
Bisphosphonates – Bisphosphonates, the anti-resorptive therapy, are 
analogues of pyrophosphate and have strong affinities for bone apatite. 
Bisphosphonates are potent inhibitors of bone resorption and elicit effects by 
reducing the recruitment and activity of osteoclasts as well as inducing 
osteoclast apoptosis. Due to the structural similarity to inorganic 
pyrophosphate, non-nitrogen containing bisphosphonates are incorporated 
into molecules of newly formed adenosine triphosphate (ATP) after 
osteoclast-mediated uptake from the bone mineral surface (Russell, 2006). 
Intracellular accumulation of these nonhydrolyzable ATP analogues results in 
cytotoxicity and subsequent osteoclast apoptosis.   Nitrogen-containing 
bisphosphonates have a distinct mechanism of action. By inhibiting the 
mevalonate pathway, these compounds interfere with the isoprenylation of 
guanosine triphosphate binding proteins and thereby inhibit cytoskeletal 
reorganization, membrane ruffling and lead to osteoclast apoptosis (Kavanagh 






Nitrogen-containing bisphosphonates such as alendronate, ibandronate and 
zolendronate, are currently the most widely prescribed group of 
bisphosphonates (Drake et al., 2008). Although effective at suppressing 
osteoclast activity, bisphosphonates are associated with adverse side effects. 
The incidence of osteonecrosis of the jaw (ONJ) has been reported to occur at 
1 in 10 000 patients for intravenous administration of bisphosphonates 
(Khosla et al., 2007) and this risk increases with the use of the more potent 
bisphosphonates. ONJ may remain asymptomatic for up to years, and may 
result in pain or exposed maxillary or mandibular bone following 
inflammation or infection. Signs and symptoms that may occur before the 
development of clinically detectable osteonecrosis include pain, tooth 
mobility, mucosal swelling, redness and ulceration. Although these signs and 
symptoms may occur spontaneously, they commonly develop at the site of 
earlier dentoalveolar surgery. Although the mechanism by which 
bisphosphonates lead to ONJ is not fully understood, the pathogenesis of this 
process is consistent with defective jawbone physiologic remodeling and 
wound healing (Rodan & Fleisch, 1996). It has been suggested that 
bisphosphonates, as a result of osteoclast inhibition and apoptosis, interferes 
with bone remodeling. Furthermore, bisphosphonates have also been shown 
to inhibit endothelial cell proliferation (Fournier et al., 2002) and have 
antiangiogenic properties (Wood et al., 2002), thereby impeding wound 
healing.  
 
Bisphosphonates, by disrupting osteoclast function, suppresses bone 





atypical fractures (Odvina et al., 2005). Bisphosphonate-associated atypical 
fractures are low trauma-induced stress fractures in the compact bone at the 
subtrochanteric femur and femoral shaft. A cohort study by Schilcher, 
Michaëlsson, and Aspenberg (2011) involving 13 000 women treated with 
bisphosphonates showed that the age-adjusted risk of atypical fractures 
increased by 47.3% when treated with bisphosphonates and this risk 
increased with a longer duration of use. It has also been reported that 
intravenous zoledronic acid therapy is associated with a significantly 
increased risk of atrial fibrillation (Black et al., 2007). Additionally, short-term 
adverse effects such as upper gastrointestinal side effects and musculoskeletal 
pain are common among patients, typically affecting adherence rates.  
 
Parathyroid hormone (PTH) – Under physiological conditions, PTH stimulates 
both bone formation and resorption. However, intermittent administration of 
PTH or teriparatide (1-34 N terminal fragment of PTH) results in an increase 
in the number and activity of osteoblasts, thereby leading to an increase in 
bone mass and an improvement in skeletal architecture (Aslan et al., 2012). 
Treatment with both agents has been shown to significantly reduce the risk of 
vertebral fractures in postmenopausal women (Neer et al., 2001). 
Additionally, the beneficial effects of teriparatide on non-vertebral fractures 
have been demonstrated to persist for up to 30 months after discontinuation 
of treatment (Prince et al., 2005). 
 
Common adverse events in patients treated with PTH or teriparatide are 





family is contra-indicated in patients with renal impairment, and 
osteosaracomas. A major drawback of PTH hormone therapy is the need for 
daily subcutaneous administration, Furthermore the safety of PTH therapy 
has only been demonstrated for a maximum of 24 months (Prince et al., 2005).  
 
Strontium ranelate – Strontium ranelate has been shown to exert dual actions 
on bone, enhancing bone formation (Fernandez et al., 2014), while inhibiting 
resorption (Caudrillier et al., 2010), thereby leading to increases in bone 
mineral density and reducing fracture risk by ~30% in the hip and vertebrae 
(Meunier et al., 2004; Stepan, 2013). Common side effects of strontium 
ranelate treatment include nausea and diarrhea. However, strontium ranelate 
has also been shown to lead to significant increases in serum levels of calcium 
leading to serious cardiac side effects and venous thrombo-embolism (Audran 
et al., 2013). Though rare, strontium ranelate administration has been 
reported to be associated with severe, potentially lethal skin reactions such as 
the drug reaction with eosinophilia and systemic symptoms (DRESS) (Jonville-
Bera & Autret-Leca, 2011). Due to the severity and number of possible adverse 
side effects, strontium ranelate is not recommended as the first choice 
treatment option for older patients (Bernabei et al., 2014) 
 
Denosumab – Denosumab is a human monoclonal antibody that binds to 
RANKL and prevents its interaction with the RANK receptor, thereby 
inhibiting osteoclast differentiation and bone resorption. Denosumab, given 
twice yearly for 36 months, has been shown to increase BMD by up to 7% in 





reduction in vertebral and non-vertebral fracture risk by 70% and 20% 
respectively (Cummings et al., 2009). Similar to bisphosphonates, denosumab 
treatment has also been reported to be associated with osteonecrosis of the 
jaw and atypical femoral/ subtrochanteric fractures (Bone et al., 2013; Shane 
et al., 2010). 
 
1.1.5 Estrogen deficiency-mediated osteoporosis  
It is well established that estrogen is a major hormonal regulator of bone 
metabolism in both men and women.  Falahati-Nini et al. (2000) showed that 
estrogen accounts for up to 70% of the effects of sex steroids on bone 
metabolism in men. As previously explained, the protective effects of estrogen 
on bone has been demonstrated in several clinical studies, in which HRT led to 
significant improvements in BMD and accordingly, a reduction in fracture risk 
of postmenopausal women (Cauley et al., 2003; Ettinger et al., 1999). As such, 
it is widely accepted that estrogen deficiency in women, caused by menopause 
or ovariectomy, results in osteoporosis, and much efforts have been focused 
on uncovering the mechanisms by which estrogen modulates bone turnover.  
 
At the cellular level, estrogen has been shown to reduce osteoclast resorption 
by inducing osteoclast apoptosis (Nakamura et al., 2007) and to inhibit 
RANKL-induced osteoclast differentiation (Kharkwal et al., 2012; Srivastava et 
al., 2001). Studies have also demonstrated that estrogen can regulate 
osteoclast formation and activity indirectly by reducing RANKL production by 
the T cells and osteoblast, while increasing their production of the soluble 





differentiation and activity are regulated by a variety of cytokines, including 
interleukin (IL)-1, -6, and -7, tumour necrosis factor (TNF) and RANKL 
(Horowitz, 1993; Manolagas & Jilka, 1995). Studies have revealed that 
estrogen moderates expression and production of these pro-inflammatory 
cytokines to regulate osteoclast differentiation and activity (Cenci et al., 2000; 
D'Amelio et al., 2008; Roggia et al., 2001). Ex-vivo studies have shown greater 
production of IL-1 from the human peripheral blood monocytes obtained from 
untreated osteoporotic women compared with estrogen-treated 
postmenopausal women or untreated premenopausal women (Pacifici et al., 
1991). Although it has largely been established that the protective effect of 
estrogen is mediated in part by suppressing cytokine production, there remain 
controversies over the precise target cells of estrogen. 
 
Estrogen deficiency leads to an imbalance in bone remodeling, in particular a 
net increase in bone resorption, thereby leading to osteoporosis (Khosla et al., 
2012). It has been shown that estrogen improves the balance in bone 
remodeling by inhibiting apoptosis of both osteoblast and bone marrow-
derived mesenchymal stem cells in vitro (Shao et al., 2015; Yang et al., 2013). 
Both estrogen-deficiency and ageing has been associated with an increased 
production of reactive oxygen species in bone (Almeida et al., 2007), which 
has been shown to inhibit the differentiation of osteoblasts from their 
progenitors and decrease the life-span of the bone-forming cells (Almeida et 
al., 2010). The anti-oxidative properties of estrogen could therefore be an 






1.1.6 Flavonoids and osteoporosis  
Flavonoids are bioactive polyphenols found in a wide diversity of fruits and 
vegetables. Flavonoids share the same polyphenolic backbone but differ in 
their arrangement of hydroxyl, methoxy and glycosidic side groups. Based on 
their biologic activity, these compounds can be divided into two broad 
categories: (1) flavonoids or bioflavonoids, including the flavones, flavonols 
anthocyanidins, and catechins, or (2) isoflavones, also known as 
phytoestrogens. The structure, sources and representative compounds of 
these flavonoid subclasses are summarized in Table 1.3. 
 
Epidemiologic associations have been demonstrated between flavonoid intake 
and markers of bone health. In a retrospective study of 3000 peri-menopausal 
women, a positive association between total dietary flavonoid intake and bone 
mineral density of the spine and femoral neck was shown, along with a 
reduction in markers of bone resorption (Hardcastle, Aucott, Reid, & 
Macdonald, 2011). Additionally, negative associations between both catechins 
and flavanones with bone resorption markers were detected in this study. 
Welch et al. (2012) demonstrated in an observational study of 3000 women a 
positive association between anthocyanins intake and BMD at both the hip 
and spine, while flavanone intake was positively associated with hip BMD. 
Interestingly, consumption of tea, a rich source of catechins, has been reported 
to reduce the risk of hip fractures (Johnell et al., 1995). 
 
Isoflavones, the major phytoestrogen contained in soybeans, are structurally 





1998). Observational studies suggest that soy consumption contributes to low 
rates of hip fractures in Asians (Ross et al., 1991; Ye et al., 2006). In the 
Shanghai Women’s Study involving 75,000 women, hip fracture prevalence 
was inversely related to soy consumption (Zhang et al., 2005). Furthermore, a 
stronger relationship was detected in early (< 10 years) rather than late 
menopausal women. This discrepancy could be due to a greater 
responsiveness to soy isoflavones during the early phase of estrogen 
deficiency. Interestingly, soy isoflavones have been shown to lead to a 
decrease in urine deoxypyridinoline, a bone resorption marker, but did not 
lead to significant changes in serum bone formation markers alkaline 
phosphatase and osteocalcin, which could account for the greater 
responsiveness to soy isoflavones during the early phase of estrogen-
deficiency when there is increased bone resorption (Eghbali-Fatourechi et al.; 
Taku et al., 2011). Meta-analysis of randomized controlled trials involving the 
dominant soy isoflavone revealed that 120 mg of genistein aglycone was 
modestly protective for femoral neck BMD compared with placebo (Shedd-
Wise et al., 2011). Morabito et al. (2002) showed in a double-blind 
randomized controlled trial of postmenopausal women that genistein 
treatment was as effective as HRT in inhibiting bone turnover, leading to 






Table 1.3 Occurrence of flavonoids in foods 




Onion, kale, broccoli, 
apples, cherries, 



















berries, red wine, 
strawberries, fruit 





Soy beans, legumes Dadzein, genistein 








1.2 Bone metabolism 
Bone is a composite material made up of approximately 70% mineral 
(hydroxyapatite), 22% proteins such as Type I collagen and 8% water by 
weight. As a vital component of the skeletal system, bone plays a role in 
several physiological functions: first, it has a structural function in providing 
support and protection of vital internal organs and bone marrow, as well as 
muscle attachment sites to enable locomotion. Second, the skeleton, as a 
reservoir of calcium and phosphate, has an essential metabolic function in 
maintaining serum homeostasis of these ions. Third, the red bone marrow 
housed within the skeleton contains haematopoietic stem cells essential for 
the production of blood cells. 
 
1.2.1 Macroscopic organization of bone  
Bone tissue is classified as either compact/ cortical bone or spongy bone 
depending on the organization of the bone matrix and cells. Bones in the body 
can be made up of both the compact and spongy bone. The physical structure 











Compact bone forms the outer layer of all bones. It provides protection and 
support to the bone and enables long bones to bear the stresses placed on 
them. Compact bone is loaded mostly by bending moments, resulting in a high 
percentage of tensile stresses (Augat & Schorlemmer, 2006). The hardness of 
cortical bone is associated with its mineral content and bone density, whereas 
its strength is associated with the quality and orientation of the collagen 
matrix.  
 
Figure 1.1 Structure of a long bone. The articular cartilage reduces friction at the 
articulating joints and acts as a shock absorber. The endosteum is a membrane that 
lines the cavity of bones. The periosteum is the tough fibrous membrane that covers 







The osteon, otherwise known as the Harversian system, makes up the basic 
three-dimensional unit of compact bone (Fig. 1.2). Each Harversian system 
comprises of the following parts: 
(a) A central Harversian canal that contains blood vessels and nerves. The 
harversian canal is surrounded by layers of  
(b) Lamellae, which are concentric rings of matrix formed from calcium and 
phosphate salts that crystalize around the collagen fibres.  
(c) Lacunae are small spaces between the lamellae in which osteocytes are 
located. 
(d) Canaliculi are minute channels that link the lacunae and provide routes by 
















The spongy bone is made up of an irregular lattice of trabecular bone, which 
contains lamellae, osteocytes, lacunae and canaliculi. Blood vessels from the 
periosteum penetrate into the trabecular lattice to provide nutrients to the 
osteocytes. Red bone marrow present within the spongy bone is responsible 
for production of red blood cells, platelets and white blood cells.  
 
1.2.2 Bone remodeling 
 
Bone is a dynamic tissue that undergoes constant remodeling in response to 
mechanical loads. The remodeling process is the manner in which bone tissue 
is renewed, with about 10% of bone material renewed each year (Lerner, 
2006).  This remodeling process (described in Fig. 1.3) is organized in the 
basic multicellular unit (BMU) and is crucial for the maintenance of the quality 
and size of the skeleton. The BMU is a temporary anatomic structure that 
comprises of the osteoblasts, osteocytes and osteoclasts, covered by a canopy 
of bone lining cells. Bone remodeling requires the coordinated action of these 
cell types. It has been demonstrated that the rate of advancement of the BMU 
in the direction parallel to the long axis of bone proceeds at approximately 25 
μm/day (Jaworski, 1992). This advancement of the BMU persists for 6 – 9 
months (Jilka, 2003). 
 
The remodeling process involves four major but overlapping phases (Feng & 
McDonald, 2011): 





Phase 2 – bone resorption along with the simultaneous recruitment of 
mesenchymal stem cells (MSCs) 
Phase 3 – osteoblast differentiation and its function in osteoid synthesis 
Phase 4 – mineralization of the osteoid 
 
It has been proposed that osteocytes are the cells responsible for initiating 
bone remodeling by transmitting an as yet unidentified signal to recruit 
osteoclast precursors to specific bone sites. Bone remodeling is initiated in 
response to bone deformation as a result of mechanical loading or 
microdamage in old bone (Parfitt, 2002).  The bone-remodeling compartment 
is a closed system that is highly vascular and is characterized by a canopy of 
bone-lining cells. Osteoclast precursors may be recruited from the bone 
marrow or from capillaries that penetrate into the remodeling compartment. 
The osteoclast precursors then attach to the surface of bone and differentiate 
into osteoclasts (greater detail in following section), resorbing trenches that 
are 40 – 60 μm deep (Hadjidakis & Androulakis, 2006). The remodeling 
process proceeds to Phase 2 in which bone resorption is the predominant 
event. In phase 2, MSCs are also recruited from the bone marrow or capillaries 
and differentiate into preosteoblasts and osteoblasts. In phase 3, osteoid 
synthesis supersedes bone resorption as the predominant event. Of the four 
phases, phase 3 continues for the longest amount of time to allow more bone 
to be replaced with osteoids produced by the osteoblasts. The osteoids are 
mineralized in phase 4 to conclude the remodeling cycle (Proff & Römer, 













  Figure 1.3 Bone remodeling in the basic multicellular unit. During bone turnover, 
bone-lining cells shift away from the bone surface to allow the osteoclasts, that proceed 
in front, and osteoblasts, that follow behind, to perform their respective functions. 
Monocytes enter the remodeling site and undergo differentiation in the presence of the 
Receptor Activator of NFκB Ligand (RANKL) to become a mature osteoclast, which 
then initiates bone resorption. The osteoblast precursors, mesenchymal stem cells 
(MSC), also enter the remodeling site and undergo osteogenic differentiation into 
mature osteoblasts. Functional osteoblasts then mineralize the areas it is adhered to. In 
addition, osteoblasts express RANKL, necessary for osteoclast differentiation, as well as 
OPG, which are decoy recptors that bind RANKL. The osteoblasts therefore modulate 
osteoclast differentiation via its relative expression of RANKL: OPG. Adapted from 










Osteoblasts are derived from the multipotent mesenchymal stem cells found 
in the bone marrow. These mesenchymal stem cells possess the ability to 
differentiate into osteoblasts, adipocytes, mycoytes, neurons, and 
chondrocytes. The release of growth factors from the bone matrix during bone 
resorption activates osteoblast differentiation (Udagawa, 2012). The 
osteoblasts line the surfaces of bone and are responsible for synthesizing and 
secreting organic bone material.  These cells produce a combination of 
extracellular proteins, including osteocalcin, alkaline phosphatase and 
collagen fibrils. The extracellular matrix, made up of type I collagen, is known 
as the osteoid prior to its mineralization with calcium phosphate. Osteoblasts 
express RANKL, crucial for the osteoclast differentiation process (as will be 
further described below). By secreting osteoprotegerin (OPG), the soluble 
decoy peptide that binds to RANKL and prevents the ligand from binding to its 
receptor, osteoblasts are able to modulate osteoclast differentiation. 
Replacement of resorbed bone by a group of osteoblasts is a process that takes 
approximately 3 months (Jilka, 2003). After which, the remaining osteoblasts 
that have not undergone apoptosis or become embedded in the bone matrix 
will become the bone-lining cells over the quiescent bone surface (Boyce et al., 
2002; Parfitt, 1990).   As such, the lifespan of the osteoblast is approximately 






The differentiation of osteoblasts is divided into stages of mesenchymal 
progenitors, preosteoblasts and mature osteoblasts. Preosteoblasts include all 
cells transitioning from mesenchymal progenitors into mature osteoblasts. 
While osteoblasts are characterized by the expression of osteocalcin, 
molecular markers for mesenchymal progenitors and preosteoblasts include 




Osteoblasts that are trapped within the collagenous matrix are calcified to 
form osteocytes. These cells are regularly dispersed throughout the 
mineralized matrix and are the most abundant cell type in bone.  Osteocytes 
extend dendritic processes through the bone in “tunnels” known as cannaliculi 
to facilitate communication with each other and the bone lining cells and 
osteoclasts. Given that osteocytes make up 90-95% of all bone cells, coupled 
with their wide distribution through the bone matrix and high degree of 
interconnectivity, it has been suggested that the osteocytes function as 
mechanosensors that transduce mechanical strain into biochemical signals to 




Osteoclasts are the cells responsible for bone resorption. These 
multinucleated cells originate from the hematopoietic lineage and are formed 
from fusion of mononuclear progenitors such as monocytes or bone marrow 
macrophages. Receptor activator of NFκB  (RANK) is expressed on the 





critical osteoclastogenic cytokine, macrophage colony stimulating factor 
(MCSF). Additionally, MCSF induces the proliferation of the osteoclast 
precursors and enhances the survival of osteoclasts (Teitelbaum, 2000). The 
binding of RANKL to its receptor leads to the differentiation and fusion of 
mononuclear precursors into multinucleated osteoclasts (Fig. 1.4). The mature 
multinucleated osteoclasts, expressing tartrate-resistant acid phosphatase 
(TRAP), undergo cytoskeletal reorganization to attach to the surface of bone 
through the formation of the actin-bound sealing zone (Boyce et al., 2003). 
The sealing zone, as its name suggests, seals the resorbing lacuna and 
segregates this microenvironment from the extracellular environment. The 
ruffled border is a specialized membrane that is formed within the 
circumferential sealing zone and is the site of active secretion. Within the 
sealing zone, the osteoclasts secrete proteolytic enzymes such as Cathepsin K 
and matrix metalloproteinase to break down the collagenous matrix. 
Osteoclasts also maintain an acidic pH within the sealing zone to dissolve the 
inorganic bone matrix, leading to the formation of resorption pits (Rousselle & 
Heymann, 2002). The osteoclast is a prominently polarized cell with the 
functional secreting domain, involved in transcytosis of degraded matrix 
products, located opposite to the ruffled border (Coxon & Taylor, 2008; 
Takahashi et al., 2007).  
 
It has also been demonstrated that osteoclast differentiation is regulated by 
various cytokines such as Interleukin (IL)- 1, -7, and tumour necrosis factor 
(TNF). IL-1 and TNFα are potent cytokines that have been shown to induce 





TNFα have synergistic effects with RANKL on inducing osteoclast formation to 
upregulate expression of osteoclast-specific genes. Further, RANKL also 
enhances the expression of IL-1 receptor type I to perpetuate osteoclast 
differentiation (Kim et al., 2009). IL-1 and TNFα enhance osteoclast 
differentiation both directly and indirectly. At the molecular level, both 
cytokines activate pathways that overlap significantly with RANKL-induced 
signaling cascades (Zhang et al., 2001). IL-1 and TNFα also increase stromal 
cell production of IL-7. IL-7 indirectly induces differentiation of osteoclast 
precursors into mature activated osteoclasts by stimulating T-cells production 
of osteoclastogenic cytokines (Weitzmann et al., 2000). Indeed, it has been 
suggested that estrogen withdrawal increases the production of pro-
inflammatory cytokines that drive osteoclast formation and resorption, 
















Figure 1.4 Osteoclast differentiation process and bone resorption. RANKL, upon 
binding to its receptor, RANK, commits a monocyte to osteoclast differentiation. This leads 
to the expression of osteoclast-specific genes such as the fusion receptor dendritic cell-
specific transmembrane protein (DC-STAMP) and secretory enzymes Cathepsin K (CthK), 
matrix metalloproteinase-9 (MMP-9), and tartrate-resistant acid phosphatase (TRAP). DC-
STAMP enhances cell-to-cell fusion of the mononuclear osteoclasts to form a giant 
multinucleated osteoclast, which attach to the surface of bone by forming the sealing zone. 
The αvβ3 integrin binds to RGD-containing peptides present in abundance in bone and has 
been shown to play a role in osteoclast movement (Holt & Marshall, 1998). Active secretion 
by osteoclasts occurs at the ruffled border of the plasma membrane. The osteoclasts 
maintain an acidic pH in the resorption zone and release enzymes such as CthK, MMP-9, 






 1.3 Osteoclastogenesis and the RANKL/RANK signaling 
pathway 
The binding of RANKL to its receptor, RANK, triggers signaling cascades that 
regulate osteoclast differentiation and activation (Fig. 1.5). The RANK receptor 
protein, a member of the tumour necrosis factor (TNF) receptor super family, 
lacks intrinsic kinase activity and relies on the recruitment of intermediate 
adaptor proteins to activate downstream signaling pathways (Darnay et al., 
2006; Walsh, 2014). Activation of RANK is followed by the receptor’s 
trimerization and recruitment of TNF receptor associated factors (TRAFs) that 
facilitate activation of downstream signaling cascades such as the NFκB, 
MAPK/AP-1, phosphatidylinositide 3-kinase (PI3K)/AKT signaling pathways 
(Darnay et al., 2006; Kim & Kim, 2016). Activation of these signaling cascades 
mediate the expression and activity of nuclear factor of activated T cell-1 














Figure 1.5 RANKL/RANK signaling pathway. The binding of RANKL to its receptor, 
RANK, triggers the RANKL signaling cascade in vitro. The RANKL signaling cascades 
include the NFκB (blue arrows), MAPK (green arrows) and cSrc/PI3K/Nox1 (orange 
arrows) pathways, which are modulated via recruitment of the TNF receptor associated 
factor 6 (TRAF6) adaptor protein. This leads to increased nuclear translocation of 
transcription factors NFκB and AP-1, thereby increasing gene expression of the NFATc1 
transcription factor. RANKL, by activating the Nox1 enzyme, also induces an increased 
production of intracellular ROS, which then activates the phosphatase calcineurin, thus 
increasing nuclear translocation of NFATc1. NFATc1 leads to increased expression of 
osteoclast-specific genes as previously explained, thereby regulating osteoclast 
differentiation. (Not shown in this diagram) The binding of M-CSF to its surface receptor c-
Fms results in dimerization of the receptor and activation of receptor tyrosine kinase (RTK) 
ultimately leading to increased differentiation into, proliferation of osteoclast precursors, 






1.3.1 Importance of TRAF6 in RANK signaling 
The TRAF family consists of seven known proteins that function as adaptors 
for the TNF-receptor super family. Although Pullen et al. (1999) demonstrated 
that TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6 interact with the cytoplasmic 
domain of RANK, only TRAF2, TRAF5 and TRAF6 have been demonstrated to 
be functionally competent in activating downstream signaling pathways, given 
that specific deletion of these TRAF-binding regions on the cytoplasmic 
domain of RANK resulted in failure to activate NFκB in vitro (Darnay et al., 
1998). The significance of TRAF6 in bone metabolism was made apparent 
with TRAF6 deficient mice exhibiting defective osteoclastogenesis and severe 
osteopetrosis (Lomaga et al., 1999), however, the functional significance of 
TRAF2 and TRAF5 in osteoclastogenesis remains to be elucidated, given that 
TRAF2 and TRAF5 deletion in mice did not lead to osteopetrosis (Galibert et 
al., 1998)   . 
The N-terminal of TRAF6 comprises of a RING finger domain and 
consequently, TRAF6 has also been shown to function as a ubiquitin E3 ligase 
(Wang et al., 2001; Wu & Arron, 2003). However, the primary function of 
TRAF6 is not to target proteins for proteasomal degradation but to activate 
downstream signaling cascades. Indeed, it has been suggested that auto-
ubiquitination of TRAF6 via lysine63-linked polyubiquitin chains is crucial for 
the formation of complexes that activate downstream cascades (Kanayama et 
al., 2004). Additionally, TRAF6 catalyzes lysine63-linked polyubiquitin chains 
to mediate activation of TGFβ-activated kinase 1 (TAK1) that further activates 





(Deng et al., 2000; Mizukami et al., 2002). 
 
1.3.2 NFκB signaling cascade in osteoclast differentiation 
As suggested by its name, stimulation of RANK leads to strong activation of the 
Nuclear Factor of κB (NFκB) transcription factors. RANKL, via TRAF6, rapidly 
stimulates the activation of the classical and alternative NFκB pathways in 
osteoclast precursor cells. The NFκB family is a group of dimeric transcription 
factors that consists of five members: cRel, RelA (p65), RelB, NFκB1 
(p105/p50) and NFκB2 (p100/p52). TRAF6 facilitates ubiquitination of TAK1 
and two adaptor molecules, TAB1/2, leading to activation of the classical 
NFκB pathway, by activation of the inhibitor of κB (IκB) kinase (IKK) complex. 
cRel, p65 and p50 are sequestered in the cytoplasm by IκB proteins.  The IKK 
complex phosphorylates IκB, leading to its proteasomal degradation, thereby 
releasing the bound NFκB dimers to translocate to the nucleus (Fig 1.5, blue 
arrows). In the alternative pathway, NFκB-inducing kinase (NIK) and IKKα 
induces the phosphorylation-dependent proteolytic cleavage of NFκB2, 
allowing RelB-p52 dimers to translocate to the nucleus. 
 
The importance of the NFκB family of dimeric transcription factors to 
osteoclastogenesis was revealed when deletion of the NFκB1/p50 and 
NFκB2/p52 subunits led to severe osteopetrosis in mice as a result of 
osteoclast deficiency (Iotsova et al., 1997; Monje et al., 2005). While RANKL 
has also been shown to activate the alternative NFκB pathway by triggering 





dimer (Novack et al., 2003), it remains unclear which of the two NFκB 
pathways are dominant in osteoclast differentiation. Nevertheless, Asagiri et 
al. (2005) have shown using ChIP experiments that the p50-p65 subunits are 
recruited to the NFATc1 promoter following RANKL stimulation, indicating 
that these NFκB components are crucial in regulating the expression of 
NFATc1.  
 
1.3.3 MAPK/AP-1 signaling cascade in osteoclast differentiation 
C-Fos, a member of the AP-1 family of transcription factors, has been shown to 
be indispensable for osteoclast differentiation given the osteopetrotic 
phenotype of c-Fos knockout mice (Grigoriadis et al., 1994; Wang et al., 1992). 
It was further delineated that c-Fos is crucial to the induction of NFATc1 since 
recruitment of c-Fos to the NFATc1 promoter has also been demonstrated. 
Additionally, induction of NFATc1 mRNA by RANKL is abrogated in c-Fos 
deficient cells (Asagiri et al., 2005; Iotsova et al., 1997).  Given that c-Fos can 
only heterodimerize with members of the Jun family to form the AP-1 
heterodimer, Soysa and Alles (2009) demonstration that expression of 
NFATc1 is Fos/Jun dependent is in keeping with the presence of AP-1 
response elements in the NFATc1 promoter (Asagiri et al., 2005). 
 
Expression and activity of the AP-1 transcription factor is regulated by the 
mitogen-activated protein kinases JNK, ERK and p38 (Fig 1.5, green arrows). 
The c-Jun N-terminal Kinase (JNK) regulates transcriptional activity of c-Jun 
by phosphorylation of two serine sites within the transcriptional activation 





kinase (ERK) has been shown to increase expression of c-Fos, while 
phosphorylation of the transactivation domain of c-Fos by p38 increases the 
transcriptional activity of AP-1 (Monje et al., 2005; Novack et al., 2003). 
Additionally, there is a wealth of studies demonstrating that RANKL induces 
activation of the JNK, ERK and p38 kinases, that when disrupted interferes 
with osteoclast differentiation in vitro (Kashiwada et al., 1998; Matsumoto et 
al., 2000). Hence, MAPK regulated AP-1 expression and activity is crucial for 
the expression of NFATc1 and osteoclast differentiation. 
 
 
1.3.4 Intracellular ROS in osteoclast differentiation 
There has been a recent accumulation of evidence supporting the importance 
of intracellular reactive oxygen species (ROS) as a secondary messenger in 
RANKL-mediated osteoclastogenesis (Kim et al., 2010; Lee et al., 2005; Lee & 
Jang, 2015; Moon et al., 2011). It was demonstrated that RANKL, by 
recruitment of TRAF6, activates a signaling cascade involving cSrc, PI3K and 
the Rac1 GTP-ase in order to activate the Nox1 enzyme responsible for the 
intracellular ROS production (Fig 1.5, orange arrows). While N. K. Lee et al. 
(2005) demonstrated that this increase in intracellular ROS occurs in the 
acute time frame (within 30 min) following RANKL stimulation and lies 
upstream of MAPK activation, M. S. Kim et al. (2010) showed that the chronic 
(> 24 hours) and not acute transient ROS production following RANKL 
stimulation mediates calcineurin activation via calcium oscillations. RANKL 
induces phosphorylation and activation of phospholipase-Cγ (PLCΥ) which 
then increases intracellular Ca2+ levels ([Ca2+]i) via several sequential steps: 





triphosphate (IP3). IP3 binds to IP3-receptors in the endoplasmic reticulum 
triggering the release of Ca2+ from ER stores. The increase in [Ca2+]i leads to 
activation of calcineurin, which dephosphorylates several phosphoserines on 
NFATc1 to allow its nuclear translocation and activation (Hogan, 2003). 
Indeed, Kim et al. (2010) showed that application of the ROS scavenger, N-
acetyl cysteine (NAC), or a Nox1 inhibitor, abrogated RANKL-induced [Ca2+]I 
oscillations, indicating that RANKL-induced ROS production is crucial for 
mediating calcineurin activation. Furthermore, both studies demonstrated the 
importance of intracellular ROS production to osteoclast differentiation, 
where application of NAC, or silencing the expression of Nox1 completely 
abolished osteoclast formation.  
 
The anti-osteoclastogenic effects of compounds such as genistein (Lee et 
al., 2014), resveratrol (He et al., 2010), scoparone (Lee & Jang, 2015) and 
rutin (Kyung et al., 2008) have also been attributed to their anti-oxidative 
properties.  
 
1.3.5 Role of NFATc1 in osteoclast differentiation 
As previously described, NFATc1 activation is initiated by dephosphorylation 
of the NFAT regulatory domain. This domain, heavily phosphorylated in 
resting cells, is dephosphorylated by calcineurin to trigger NFATc1 nuclear 
accumulation and enhance its transcriptional activity (Beals et atl., 1997; 
Okamura et al., 2000). The importance of NFATc1 to osteoclast differentiation 
was demonstrated with NFATc1-deficient stem cells’ inability to differentiate 





causes embryonic stem cells to undergo efficient differentiation in the absence 
of RANKL signaling (Takayanagi et al., 2002).  It has been suggested that the 
exclusive function of NFATc1 in osteoclastogenesis is a result of an NFATc1-
specific gene regulatory mechanism. In support of this hypothesis, RANKL 
induces NFATc1 selectively and potently, while NFATc2 mRNA is expressed 
constitutively in precursor cells at a low basal level. Furthermore, ChIP 
experiments revealed that NFATc1 but not NFATc2 is recruited to the NFATc1 
promoter after RANKL stimulation, indicating that autoamplification 
mechanism by NFATc1 is specifically operative in its promoter. Based on 
promoter analysis, it was found that NFATc1 directly regulates multiple 
osteoclast-specific genes. These include TRAP, Ctsk, calcitonin receptor, and 
αvβ3 integrin (Matsumoto et al., 2000; Takayanagi et al., 2002). AP-1 is a 
known transcriptional partner of NFAT in lymphocytes and the NFATc1:AP-1 
complex is important for the induction of TRAP, calcitonin receptor genes as 
well as amplification of NFATc1. NFATc1 also forms an osteoclast-specific 
transcriptional complex containing AP-1 (Fos/Jun) and microphthalmia-
induced transcription factor (MITF) for efficient induction of osteoclast-
specific genes (Takayanagi, 2007). The components of the NFATc1 
transcriptional complex are not always the same suggesting that differential 
composition of the transcriptional complex contributes to spatiotemporal 






1.4 Epimedium (Berberidaceae) for bone health 
 
The dried aerial parts of Epimedium (Berberidaceae), colloquially known as 
Yin Yang Huo, have been used by traditional chinese medicine practitioners to 
treat a number of conditions. The use of this herb was first prescribed in the 
Copendium of Materia Medica (Bencao Gangmu), written in 1578. The 
Epimedium genus comprises of 52 species of herbaceous plants (Stearn, 
2002). This herb is used popularly either singularly or in combination with 
other herbs to treat a plethora of conditions such as osteoporosis, 
cardiovascular diseases, sexual dysfunction and menstrual irregularity (Meng 
et al, 2005; Zhang et al, 2006). 
 
1.4.1 Chemical constituents of the genus Epimedium 
More than 260 compounds have been identified in the plants of the 
Epimedium genus (Ma et al., 2011), of which prenylflavonoids have been found 
to be the major constituents, forming more than 50% by weight of ethanolic 
extracts (Shen et al., 2007). Icariin is the most abundant compound, forming 
up to 6.5% of the dried weight of an ethanolic extract, and is therefore used as 
the chemical marker for the standardization of the quality of Epimedium 
extracts (Chinese Pharmacopeia, 2010). When consumed orally, the flavonoid 
glycoside is deglycosylated to form the main active metabolites icaritin and 
desmethylicaritin (Fig. 1.6). The osteogenic properties of Epimedium 
compounds demonstrated in both preclinical and clinical studies have been 








Figure 1.6 Structures of Icariin and its derivatives. Icariin when consumed orally, is 
deglycosylated with the removal of its rhamnose (Rha) and glucose (Glu) to form the 






1.4.2 Effects of icaritin on bone  
 
Bone formation 
Icaritin enhances rat osteoblast proliferation and differentiation, leading 
to increased calcium deposition and increased mRNA expression of 
osteoblast genes (Huang et al., 2007). Icaritin has also been shown to 
enhance osteogenic differentiation of human MSCs to osteoblasts under 
osteogenic induction conditions while inhibiting adipogenic differentiation 
(Yao et al., 2012).  Peng et al. (2013) showed that icaritin treatment that began 
one month but not three months post-ovariectomy led to a significant 
improvement in the bone architecture and strength of the OVX rats. Ex-vivo 
culture of bone marrow stromal cells (BMSCs) from icaritin-treated OVX rats 
also showed increased osteogenic differentiation along with suppressed 
adipogenesis. The osteogenic effects of icaritin have also been demonstrated 
in bone defect repair models (Chen et al., 2013; Qin et al., 2015; Wang et al., 
2013). Icaritin, when incorporated in a poly lactic-co-glycolic and tricalcium 
phosphohate scaffold to enable its sustained release, significantly reduced the 
incidence of femoral head collapse and led to improved mechanical properties 
by enhancing new bone formation (Qin et al., 2015). Mechanistic studies 
revealed that icaritin led to increased BMSCs recruitment into the icaritin-
incorporated scaffolds and led to the increased expression of osteogenesis-









Huang et al. (2007) demonstrated that icaritin treatment inhibits osteoclast 
formation in vitro and suppressed RANKL-induced ROS production in RAW 
264.7 mouse macrophage cells. Interestingly, icaritin was found to exhibit a 
significantly greater inhibition on osteoclast actin ring formation than 
icariside, icariin, and the soybean isoflavone, genistein. Peng et al. (2013) 
showed that early icaritin treatment inhibited bone resorption in the OVX rats 
and led to decreased osteoclast-related gene expression in bone homogenates. 
However, the molecular mechanisms by which icaritin inhibits osteoclast 
formation and resorption have not been identified. 
 
1.4.3 Dietary source of icaritin  
As previously outlined, icaritin is the main prenylflavonoid derived from the 
Epimedium species of herbs when consumed orally. Zhang et al. (2007) 
demonstrated in the randomized double-blind placebo-controlled trial that 24 
months’ treatment with 60 mg icariin, 15 mg dadzein and 3 mg genistein daily 
lead to significant improvements in lumbar spine BMD. Zhu et al. (2012) 
studied the effects of the capsular form of the Fufang Xian Ling Gu Bao 
decoction in postmenopausal women, and although effective in improving 
BMD, subjects needed to consume a daily minimum of 3g of the decoction. 
Thus, the primary disadvantage of using Epimedium-derived flavonoids or its 
herbal formulas is the daily requirement of a high drug volume/ dosage, which 
has been reported to lead to low adherence levels due to side effects in the 
digestive tracts. Nevertheless, this drawback can be resolved by identifiying 





developing an extraction method that enriches the concentrations of the active 
compound(s).   
1.5 Cellular models of osteoclastogenesis 
Since osteoclasts are derived from haematopoietic precursors, in vitro models 
of osteoclastogenesis involve the differentiation of monocytes/ macrophages 
or splenocyte precursors. Prior to the discovery that osteoblasts or marrow-
derived stromal cells release an osteoclast differentiation factor (Quinn et al., 
1998), that has since been identified as RANKL (Yasuda et al., 1998), 
haematopoietic cells or monocytes used to be co-cultured with osteoblasts/ 
stromal cells. However, the presence of recombinant MCSF and RANKL have 
allowed in vitro differentiation of the precursor cells and cell lines that are 
commonly used. 
 
1.5.1 Osteoclast-generating cocultures 
In this co-culture system, the osteoblast cultures must first be prepared. These 
osteoblast cultures can be obtained either by sequential collagenase digestion 
(Bakker & Klein-Nulend, 2012) or the use of osteoblast-like cell lines such as 
UMR 106, and allowed to reach confluence.  Osteoclast precursor cells such as 
bone marrow macrophages are typically isolated from the long bones of mice, 
or from peripheral blood as will be explained in later sections and cultured 
with the osteoblasts in the presence of Vitamin D3. At the end of the culture, 
the osteoblast/ stromal cell layer can be detached mechanically by pipetting 
PBS onto the wall of the well, or by treating co-cultures with collagenase to 





cells (Abu-Amer et al., 1997; Inoue et al., 2000). Although various techniques 
have been employed to isolate the target cells in these co-cultures, these 
procedures are unable to produce pure populations of in vitro generated 
osteoclasts that are required for biochemical and molecular analyses. 
Ensuring a consistent amount of osteoclast-differentiation stimuli released 
from the osteoblast/ stromal layer is another challenge to studying molecular 
signaling pathways in these co-culture systems. These systems, however, 
remain useful for studying interactions between osteoclasts and osteoblasts, 
and to determine cell types that are affected in the knock-out or transgenic 
mice models (Itzstein & van 't Hof, 2012).  
 
1.5.2 Osteoclast precursors 
The identification that MCSF and RANKL are indispensable for inducing 
the differentiation of haematopoietic precursors into mature 
multinucleated osteoclasts was a paradigm shift for the in vitro models of 
osteoclastogenesis. Using recombinant MCSF and RANKL, a large number 
of osteoclasts can be generated from primary osteoclast precursor cells 
(bone marrow macrophages or peripheral blood monocytes), allowing the 
study of their formation and activity in the absence of other cell types.  
 
Peripheral blood monocytes 
Peripheral blood monocytes are frequently used to generate human 
osteoclasts. In order to isolate these monocytes, the density gradient 
centrifugation method is employed to obtain the buffy coat layer 





peripheral/venous blood.  Since PBMCs are a heterogenous population of 
cells consisting of the lymphocytes and monocytes, the monocyte 
population can then be enriched by several methods. The most common 
procedure used is monocyte isolation by adherence, in which PBMCs are 
incubated in a tissue-culture treated polystyrene surface, followed by 
vigorous washing to remove the lymphocytes that have not adhered 
(Bennett & Breit, 1994). This adherence method although simple and 
convenient, has its main disadvantage in the high degree of lymphocyte 
contamination (Bennett et al., 1992). To further complicate matters, the 
degree of lymphocyte contamination varies depending on the percentage 
of lymphocytes in the PBMC, amount of PBMC laid for adherence, strength 
and number of washes (de Almeida et al., 2000). As such a high degree of 
variability is inherent in this monocyte enrichment by adherence method.  
 
Other methods for monocyte enrichment from PBMCs include immune 
selection and density gradients. Selection for the putative monocyte 
markers such as CD14 (Nicholson et al., 2000) and CD11b (Fujikawa et al., 
1996) has been shown to yield a population of cells with the ability to 
differentiate into osteoclasts. However, immune selection for monocytes is 
limited by the high costs and need for large volumes of blood in order to 
obtain a reasonable yield. Density gradient centrifugation although cost 
effective requires a high degree of manipulation of the PBMCs and has 








Bone marrow macrophages 
Another commonly used source of primary osteoclast precursors are the 
bone marrow macrophages. This method involves isolating the long bones 
from the hind limbs of mice (typically), surrounding soft tissues are 
removed, the ends of the bones are cut and the bone marrow is flushed 
out. After several washes, the macrophages are separated from the stromal 
cells by a negative adherence method. The stromal cells are allowed to 
attach to plastic petri dishes, following which the non-adherent cells are 
collected, cultured in the presence of M-CSF and allowed to adhere to 
tissue-culture treated plates. Limitations of using bone marrow 
macrophages as a source of primary osteoclast precursors include having 
to cull a live animal, limited yield, technically challenging to ensure 
sterility of the derived cell population.    
 
Limitations of using primary osteoclast precursors 
The use of primary osteoclast precursors, although more reflective of the 
native osteoclast differentiation process than immortalized cell lines, are 
models with limited applications. These cells are notoriously 
untransfectable (Cuetara et al., 2006; Marino et al., 2014) and as a result, 
are not suitable for genetic manipulation. Coupled with the fact that these 
primary cells are derived from a mixed population and fail to produce pure 
populations of in vitro generated osteoclasts, these cells have limited 
usages for the study of cellular and molecular signaling mechanisms. 





indicating constraints on cell number and need for a constant source of 
these precursors. 
 
RAW 264.7 cell line 
The RAW 264.7 murine macrophage cell line is well accepted as a cellular 
model of osteoclast formation and function (Collin-Osdoby & Osdoby, 
2012; Vincent et al., 2009). Further, this immortalized cell line has been 
identified to express the RANK receptor (Hsu et al., 1999) and the M-CSF 
receptor, c-FMS (Galal et al., 2007). RANKL has also been shown to activate 
the NFκB signaling pathway to mediate osteoclast differentiation and bone 
resorption in the RAW 264.7 cells. The use of this cell line overcomes 
several limitations of primary cells including ease of transfection, 
overcoming the need to cull a live animal, and its wide availability 
translates to a higher yield in cell number. However, since it is an 
immortalized cell line, RAW 264.7 cells may not react in a similar fashion 
to primary cells and should therefore be used in parallel with studies in 
primary cells. 
1.6 The ovariectomized rat model  
FDA guidelines have necessitated the use of the ovariectomized (OVX) rat 
model for preclinical development of anti-osteoporotic agents (Thompson 
et al., 1995). Indeed, the OVX rat is an excellent preclinical animal model as 
it emulates important clinical features of estrogen deficiency-induced 





bone following ovariectomy makes the OVX rat one of the most 
reproducible models in skeletal research (Kimmel, 1996). 
 
Following ovariectomy, a rapid loss in cancellous bone mass and strength 
occurs, which then proceeds at a less rapid rate in a site-specific fashion. 
This pattern of bone loss closely mimics that of postmenopausal bone loss 
in humans. However, cancellous bone loss does not occur at all sites in the 
rat: the distal tibial metaphysis and caudal vertebral body are known to be 
resistant to ovariectomy-induced bone loss (Li et al., 1996; Ma et al., 
1994).  Cancellous bone loss also does not proceed at the same rate at all 
sites (Table 1.4).  
 
Table 1.4 Cancellous bone changes following ovariectomy  
Site Earliest time of 
bone loss 
(days) 











~ 14  ~ 30 – 60 90 - 
Lumbar 
vertebral body 
~ 60 ~ 180- 270 270 90 
Femoral neck ~ 30 ~ 180- 270 270 90 
Adapted from (Jee & Yao, 2001) 
 
 
Since fragility fractures do not occur naturally in the OVX rat model, bone 
strength is assessed by mechanical testing of bones, such as the vertebral 






1.6.1 Shortcomings of the OVX rat model 
 
The major drawback of the rat skeleton is that some bones do not have fused 
epiphyses and have the capacity for continued bone elongation (Erben, 1996). 
As such, it is crucial to design experiments to include pre-treatment/ -
intervention controls to distinguish between cancellous bone loss, depression 
of bone growth, or a combination of both.  
 
The lack of intracortical remodeling in the rodent is the primary motivation 
behind FDA guidelines stipulating the need for preclinical evaluation of anti-
osteoporotic agents in larger animals (Thompson et al., 1995). However, there 
is growing evidence to show that the pattern and location of cortical bone loss 
in the OVX rat is almost identical to that in larger animals and humans 
(Kaneps et al., 1997; Ke et al., 1993), thus suggesting that rodent studies may 






CHAPTER 2. AIMS  
 
2.1.1 Knowledge gaps 
As outlined in the introduction, postmenopausal osteoporosis is a highly 
prevalent disease. Further, osteoporotic fractures are not only deleterious to 
the quality of life of patients; it is also a tremendous public health problem.  
Despite the treatment options available for postmenopausal osteoporosis, 
these anti-osteoporotic drugs are associated with significant clinical adverse 
events. Thus, there is a need to identify alternative treatment modalities for 
osteoporosis with improved risk-benefit profiles.  
 
Since estrogen-deficiency leads to an imbalance in bone remodeling, in 
particular, a net increase in bone resorption as a result of increased osteoclast 
numbers and activity, compounds that inhibit osteoclast formation and 
activity may be a viable treatment option. Although Epimedium flavonoids (as 
total flavonoid extracts or in herbal decoctions) have been shown to improve 
bone mineral density of postmenopausal women, the daily requirement of a 
high drug volume/ dosage, has been reported to lead to low adherence levels 
due to side effects in the digestive tracts (Zhang et al., 2006; 2007; Zhu et al., 
2012). Nevertheless, this drawback can be mitigated by identifiying the active 
molecular compound of the Epimedium-derived flavonoids.  
 
Although studies have demonstrated the osteogenic effects of icaritin in both 





icaritin on inhibiting osteoclast formation and resorption is not well 
examined. Furthermore, given the anti-oxidative properties of icaritin 
demonstrated in an animal model of myocardial ischaemia and reperfusion 
injury (Zhang et al., 2015), coupled with the important functions of 
intracellular ROS during osteoclast differentiation, perhaps icaritin inhibits 
osteoclastogenesis as a result of its anti-oxidative properties. 
  
2.1.2 Hypothesis and specific aims 
We therefore hypothesized that apart from its anabolic effects, icaritin 
improves bone health by inhibiting osteoclastogenesis and osteoclast 
resorptive function.  
 
The overall objective of this thesis was to understand the cellular 
mechanism(s) of icaritin in regulating osteoclastogenesis, and to investigate 
the therapeutic potential of icaritin in estrogen deficiency-mediated 
osteoporosis.  The specific aims of this thesis are as follows: 
 
Aim 1. To examine the functional effects of icaritin on osteoclastogenesis, and 
osteoclast bone resorptive capacity. 
(a) Using established cellular models of osteoclastogenesis, the effects of 
icaritin on osteoclast formation will be assessed by osteoclast numbers, 
expression of the osteoclast marker TRAP and expression of osteoclast-
specific genes. 





Aim 2. To elucidate the molecular mechanism(s) by which icaritin modulates 
osteoclast differentiation and resorptive function by 
(a) Examining the effects of icaritin on RANKL-induced signaling cascades: 
NFκB, MAPK/AP-1, and intracellular ROS-mediated signaling pathways. 
 
Aim 3. To investigate the therapeutic effects of icaritin in an animal model of 
estrogen deficiency-mediated osteoporosis. 
(a) Using the OVX-rat model, the effects of icaritin treatment on bone will be 
assessed by bone density, architecture and strength. Bone turnover status 
will be assessed using serum markers of bone turnover. 
(b) OVX-induced osteoclast formation will be assessed by histological analyses 
of the bone. 
(c) Effect of icaritin treatment on osteoclast-specific gene expression will be 
examined in circulating osteoclast precursors and bone homogenates. 
 




CHAPTER 3. MATERIALS & METHODS 
3.1 Cellular experiments 
3.1.1  Chemicals 
Icaritin (ICT; > 97% purity) was purchased from C-tech Global (Singapore); β-
estradiol 17-valerate (E2), N-Acetyle-L- Cysteine (NAC) and MG 132 were 
purchased from Sigma (St. Louis, MO, USA). Estrogen receptor antagonist ICI 
182,780 was purchased from Tocris Bioscience (Bristol, UK). All compounds 
were dissolved in dimethyl sulfoxide, except NAC in double-distilled deionized 
water. The final concentration of solvents in culture media was 0.1%. Bacteria-
derived recombinant mouse and human RANKL and M-CSF were purchased 
from R&D Systems (Minneapolis, MN, USA). Lipofectamine 3000 transfection 
reagent (ThermoFisher Scientific, Carlsbad, CA, USA) was used to transfect 
RAW 264.7 cells. 
 
3.1.2  Cell Culture  
RAW 264.7 mouse monocyte cell line 
RAW 264.7 cells were purchased from ATCC (TIB 71; Rockville, MD, USA) and 
were cultured in DMEM medium without phenol red containing 4.5 g/L 
glucose, 4 mM L-glutamine, 1 mM sodium-pyruvate, supplemented 10% fetal-
bovine serum and 1% streptomycin-penicillin. Cells were grown and passaged 
in a humidified incubator at 37 
◦
C with 5% CO2. 
  




Preparation and culture of human peripheral blood mononuclear cells (PBMC) 
Whole blood was obtained from healthy donors after approval from National 
University of Singapore research ethics committee. Human PBMC were 
isolated by density gradient centrifugation. Whole blood was diluted 1:1 in 
Dulbecco’s Phosphate Buffered Saline (DPBS), layered over ficoll-paque Plus 
(GE Healthcare, Amersham, UK) then centrifuged at 400 g, 18°C for 30 minutes 
with no deceleration. The buffy coat layer was collected, washed twice with 
DPBS and resuspended in the DMEM culture media described above.  
 
3.1.3  Osteoclastogenesis Assay 
RAW 264.7 cells and human PBMC were seeded in 96-well plates at a density 
of 25,000/cm2 and 1.5 x 106/cm2 respectively. After an overnight culture, 
differentiation into multinucleated osteoclasts was induced in the presence of 
50 ng/ ml RANKL and 25 ng/ ml M-CSF, supplemented with various doses of 
ICT or 10 nM E2. RAW 264.7 cells and human PBMC were cultured for 6 days 
and 21 days respectively. Differentiating media was refreshed every 2 days.  
 
Tartrate Resistant Acid Phosphatase (TRAP) staining 
After 6 or 21 days’ culture, spent media was removed, cells were fixed in pre-
warmed 4% paraformaldehyde for 10 min at room temperature and stained 
for TRAP activity (Sigma, USA). To quantify number of osteoclasts, wells were 
examined using a bright-field microscope with the 10x objective (Nikon 
Instruments). TRAP-positive multinucleated cells with >3 nuclei and a purple 
cytoplasm were counted as osteoclasts.  
 




TRAP enzyme activity 
After 6 or 21 days’ differentiation, cells were lysed with radio-
immunoprecipitation assay (RIPA) buffer (ThermoFisher Scientific, Carlsbad, 
CA, USA) containing a mini EDTA protease inhibitor cocktail (Roche Life 
Science, Madison, WI, USA). Using the acid phosphatase kit (Sigma, USA), TRAP 
activity was quantified by incubating cell lysates in the presence of a 4-
nitrophenyl phosphate substrate solution and measuring absorbance at 405 
nm. Phosphatase activity was normalized against total protein as determined 
by Bradford assay (described in Section 3.1.8). 
 
3.1.4  Osteoclast Function 
Sealing zone formation 
RAW 264.7 cells and human PBMC were differentiated in the presence of 
respective treatments on glass bottom chamber slides (Nunc LabTek, 
ThermoFisher Scientific, USA). After 6 or 21 days’ culture, cells were fixed in 
pre-warmed 4% paraformaldehyde for 10 min at room temperature. Wells 
were washed with DPBS, incubated in 0.1% Triton-X-100-PBS (Bio-Rad 
Laboratories, Hercules, CA, USA) for 10 min then stained with Alexa Fluor® 
594- phalloidin and hoechst 33342 (Molecular Probes, Carlsbad, CA, USA) in 
DPBS for 1 hour. Z-stack images were acquired with a confocal laser scanning 
microscope (Olympus FV1000, Melville, NY, USA) and analyzed using ImageJ 
(NIH, Bethesda, MD, USA). 
 
  





RAW 264.7 cells and human PBMC were differentiated in the presence of 
respective treatments on calcium hydroxyapatite-coated 24-well plates 
(Corning osteoassay surface, Corning Incorporated, NY, USA). After 6 or 21 
days, adherent cells were removed by incubating wells in 5% sodium 
hypochlorite solution and vigorous pipetting. For 2D visualization of erosion 
area, wells were imaged with a laser microscope (Olympus LEXT OLS4100, 
Melville, NY, USA). Area covered by resorption pits and erosion tracts was 
analyzed by thresholding against a blank sample in ImageJ (NIH, Bethesda, 
MD, USA) (Fig. 3.1). Three random fields were imaged for pit area 
measurements. To measure pit volume, z-stack images of the wells were taken 
with a confocal laser scanning microscope (LSM 5 meta, Carl Zeiss, UK) set in 
reflection mode. Pits were identified by contrast against a blank sample and 
negative controls. Pit volume measurements were calculated using TopoJ and 
topographical projections of z-stacks generated using SurfaceJ (ImageJ, NIH, 
US).  Six random pits were imaged per sample.  







Figure 3.1 Surface of calcium-coated well showing resorption pits and erosions 
tracts. Scale bar = 500 μm. 




3.1.5  Real-time Polymerase Chain Reaction 
For gene expression experiments, RAW 264.7 cells were plated at a density of 
30 000/cm2 in six-well plates. After subculturing for 24 h, cells were treated 
with DMSO (vehicle), ICT at doses indicated, or 10 nM E2 in DMEM 
supplemented with 10% charcoal-treated FBS, either alone or in combination 
with 50 ng/ml RANKL. 
 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA), 
according to the manufacturer’s instructions. The extracted RNA was then 
quantified using the ND-1000 Spectrophotometer (Nanodrop Technologies, 
USA). Only RNA with a quality ratio of A260/A280 between 1.9 and 2.1 was 
used for downstream analysis. The extracted RNA was reverse transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instruction. RT-PCR was 
performed using StepOnePlus RT-PCR System (Applied Biosystems, Carlsbad, 
CA, USA) following the manufacturer’s protocol using specific primers from 
Taqman® Gene Expression Assays (Applied Biosystem, USA). Relative gene 
expression values were determined by the -2∆∆Ct method with 18S rRNA as the 
reference gene. 
 
Primers for RT-PCR 
Taqman® Gene Expression Assays (Applied Biosystem, USA) 
NFATc1: Mm00479445_m1 
Cathepsin K (Ctsk): Mm00484039_m1  
TRAF6: Mm00493836_m1 





18s RNA: Mm03928990_g1 
 
3.1.6  Immunoprecipitation (IP) 
For IP assays, RAW 264.7 cells were plated at a density of 30 000/cm2 in six-
well plates. After subculturing for 24h, cells were treated with DMSO (vehicle), 
100 nM ICT in DMEM supplemented with 10% charcoal-treated FBS, either 
alone or in combination with 50 ng/ml RANKL for 24 h. Cell were lysed with 
RIPA buffer containing a mini EDTA protease inhibitor cocktail. 
 
0.4 ml of lysates was pre-cleared in Protein A/G agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) to prevent non-specific binding, at 4°C for 
60 min with gentle rocking.  Supernatant was collected and lysates were then 
incubated with 2 μg of the TRAF6 antibody and Protein A/G agarose beads (20 
μl in 50% slurry) overnight at 4°C. The lysates were washed three times with 
0.5 ml of lysis buffer, resuspended in 100 μl 2x SDS loading buffer and heated 
at 95◦C for 5 minutes.   
 
3.1.7  Cell fractionation 
RAW 264.7 cells were plated at a density of 30 000/cm2 in six-well plates. 
After subculturing for 24h, cells were treated with DMSO (vehicle), ICT at 
doses indicated, or 10 nM estradiol in DMEM supplemented with 10% 
charcoal-treated FBS, either alone or in combination with 50 ng/ml RANKL. 
After the indicated incubation durations, cells were washed with ice cold 




DPBS, removed from monolayer and collected. Cellular fractionation was 
performed according to the protocol supplied with the NE-PER kit (Pierce, 
Rockford, IL, USA). Briefly, cells pellets were resuspended in a detergent 
solution and disrupted by mechanical agitation, followed by centrifugation to 
separate the cytoplasmic and nuclear extracts.  
 
3.1.8  GTP-bound Rac1 Isolation 
RAW 264.7 cells were plated at a density of 30 000/cm2 in six-well plates. 
After subculturing for 24 h, cells were treated with DMSO (vehicle), ICT at 
doses indicated, or 10 nM estradiol in DMEM supplemented with 10% 
charcoal-treated FBS, either alone or in combination with 50 ng/ml RANKL. 
GTP-bound Rac1 was isolated using the Active Rac1 pull down and detection 
kit (Pierce, Rockford, IL, USA). After the indicated incubation durations, cell 
monolayers were washed with ice-cold DPBS, removed from monolayer and 
lysed. 20 μg GST-bound p21-binding domain (PBD) of the p21-activated 
kinase (PAK) were added to cell lysates with equal amounts of protein per 
sample. The mixture was incubated with a glutathione-resin with gentle 
agitation at 4°C for 60 min. The complexes were washed three times with lysis 
buffer not containing GST-Pak1-PBD. GTP-bound Rac1 was eluted with SDS-
loading buffer. A total of 5% of the original lysate was also electrophoresed to 
determine total levels of Rac1. 
 




3.1.9  Protein extraction & immunoblot analyses 
RAW 264.7 cells were plated at a density of 30 000/cm2 in six-well plates. 
After subculturing for 24 h, cells were treated with DMSO (vehicle), ICT at 
doses indicated, or 10 nM estradiol in DMEM supplemented with 10% 
charcoal-treated FBS, either alone or in combination with 50 ng/ml RANKL. 
 
After the indicated incubation durations, cells were washed with ice cold DPBS 
then lysed with RIPA buffer containing a mini EDTA protease inhibitor 
cocktail. Bio-Rad Bradford protein assay (Bio-Rad Laboratories, USA) was 
used to determine total protein concentration with serial dilutions of Bovine 
Serum Albumin as a standard. 20 μg of cellular protein lysates (whole cell 
lysates or subcellular fractions) in 4x SDS-loading buffer were heated at 95
◦
C 
for 5 minutes. Protein lysates or immunoprecipitates were resolved on SDS-
PAGE gel using the Mini PROTEAN 3 electropheresis cell (Bio-Rad, USA) and 
transferred onto a PVDF membrane using the semidry transfer method. After 
transfer, nitrocellulose membranes were blocked in 5% non-fat milk (Sigma, 
USA) in PBS for 1 hour. The membranes were then incubated with primary 
antibodies overnight at 4
◦
C. The membranes were washed 3 times (5 minutes 
each) with 0.1% Tween 20- PBS (PBST), then incubated with either anti-rabbit 
or anti-mouse secondary antibodies conjugated to horseradish peroxidase 
(Dako, USA) at room temperature for 2 h (1: 10 000 dilution in 5% non-fat 
milk). Protein expression signal was detected using Amersham ECL (GE 
Healthcare, Amersham, UK) and the blots were exposed to CL-XPosure Films 




(Thermo scientific, USA). The exposed films were developed using an X-Ray 
Developer (Carestream Health, USA). 
 
Primary antibodies 
The following antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). 
 P-NFATc1 (Ser 259): SC-32979 
NFATc1: SC-7294 





The following antibodies were purchased from Cell Signalling Technology 
(Beverly, MA, USA). 
MAPK pathway sampler kit: #9926 




Anti-Nox1 antibody was purchased from Abcam (ab55831; Cambridge, UK) 
and β actin from Sigma (A5316, USA). 
  




3.1.10 Cell viability assay  
RAW 264.7 cells and human PBMC were seeded in 96-well plates at a density 
of 25,000/cm2 and 1.5 x 106/ cm2 respectively. Cells were cultured until 80% 
confluence then treated with DMSO (vehicle), ICT at doses indicated, or 10 nM 
estradiol in DMEM supplemented with 10% charcoal-treated FBS, either alone 
or in combination with 50 ng/ml RANKL. After 48 h treatment, cell viability 
was determined using the standard protocol of CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (MTS; Promega, Madison, WI). The relative 
luminescence units (RLUs) were measured using a fluorescence microplate 
reader (TECAN, Maennedorf, Switzerland) at a wavelength of 490 nm. 
 
3.1.11 Immunofluorescence analysis 
RAW 264.7 cells were seeded at a density of 20 000 cells/well in 8-well glass 
bottom chamber slides (Nunc LabTek, ThermoFisher Scientific, USA). After 
overnight culture, cells were treated with DMSO (vehicle), ICT at doses 
indicated, or 10 nM estradiol in DMEM supplemented with 10% charcoal-
treated FBS, either alone or in combination with 50 ng/ml RANKL. After 
indicated durations, spent media was removed, wells were washed twice with 
DPBS and cells were fixed in pre-warmed 4% paraformaldehyde for 10 min at 
room temperature. 
 
To analyze p65 nuclear translocation, wells were incubated in 0.1% Triton-X-
100-PBS (Bio-Rad Laboratories, Hercules, CA, USA) for 10 min. This 
perforation of cell membranes was omitted where surface RANK expression 
was analyzed. Wells were washed with DPBS then blocked in 5% BSA-PBS 




solution for 1 hour and incubated with p65 (#8242, Cell Signaling Technology) 
or RANK (#4845, Cell Signaling Technology) primary antibodies overnight at 
4
◦
C.  Wells were washed thrice in 3% BSA-PBS then incubated with anti-rabbit 
secondary antibodies conjugated to a fluorescent tag (Goat anti-rabbit Alexa 
Fluor® 594 or Alexa Fluor® 488, Molecular Probes) at room temperature for 
2 h (1: 10 000 dilution in 5% BSA-PBS). Wells were washed thrice in 3% BSA-
PBS and counterstained with Hoechst 33342 (Molecular Probes). 3 random 
fields per well were imaged with a confocal laser scanning microscope 
(Olympus FV1000, Melville, NY, USA) and analyzed using ImageJ (NIH, 
Bethesda, MD, USA).  Fluorescence intensity was normalized to cell number as 
identified by the number of nuclei. 
 
3.1.12 Intracellular ROS detection  
RAW 264.7 cells were plated at a density of 30 000/cm2 in 12-well plates. 
After subculturing for 24h, cells were treated with DMSO (vehicle), ICT at 
doses indicated, or 10 nM estradiol in DMEM supplemented with 10% 
charcoal-treated FBS, either alone or in combination with 50 ng/ml RANKL. 
After indicated durations, media was aspirated, cells washed with pre-warmed 
DPBS and incubated with 10 μM CM-H2DCFDA (Molecular Probes, USA) for 30 
minutes at 37°C. Cells were removed from monolayer, washed and filtered 
through a 40 μm pore size filter. 10, 000 events were analyzed for 
fluorescence intensity with flow cytometry (CyAN ADP, Beckman Coulter, 
USA) with the excitation set at 490 nm and emission set at 510 nm. Data 
collected was analyzed with the Summit 4.3 software (Beckman Coulter). 




3.1.13 Assessment of NFATc1, NFκB and AP-1 transcriptional activities 
Plasmid information 
A pGL4.30 vector containing an NFAT response element that drives the 
transcription of the luciferase reporter gene (Luc2P) was purchased from 
Promega (Madison, WI, USA). The vector backbone contains the ampicillin 
resistance gene and a hygromycin resistance gene for mammalian selection 
(Fig. 3.2).  The pRL vector that provides constitutive expression of Renilla 
luciferase was purchased from Promega. For use as an internal control, the 
pRL vector with a relatively weak HSV-thymidine kinase promoter (pRL-TK) 
was chosen to provide neutral constitutive expression of Renilla luciferase. 
  








Figure 3.2 Map of pGL4.30 (Luc2P/NFAT-RE/Hygro) vector from Promega 





Chemically competent (One Shot® Omni-Max™ 2 T1, Thermo Scientific) cells 
were transformed with the pGL4.30 (Luc2P/NFAT-RE/Hygro) or pRL-TK 
plasmids. 50 μl of competent cells were incubated with 100 ng of plasmids at 
4°C for 20 minutes, followed by a heat-shock for 45 seconds at 42°C. Cells 
were recovered at 4°C for 2 minutes and 450 μl of SOC-LB medium (Thermo 
Scientific) was added to the cells. The mixture was incubated in a shaker (200 
rpm) for 1 hour at 37°C with 5% CO2. After which, 200 μl of the mixture was 
plated onto LB plates prepared with 50 μg/ml ampicillin, and incubated at 
37°C overnight. 
 
After the overnight incubation, a single cell colony was selected from the agar 
plate and incubated in 3 ml of LB medium containing 50 μg/ml ampicillin for 8 
hours at 200 rpm, 37°C with 5% CO2. After 8 hours, 0.4 ml of the starter 
culture was added to 200 ml of LB medium with ampicillin and cultured 
overnight at 200 rpm, 37°C with 5% CO2.After the overnight culture, cells were 
harvested by centrifugation at 6000 g for 15 minutes at 4°C. Plasmid DNA was 
isolated using a plasmid DNA purification kit (Endofree Plasmid Maxi Kit, 
Qiagen, USA). DNA concentration was determined by using the ND-1000 
Spectrophotometer (Nanodrop Technologies, USA).  
 
  




Luciferase reporter assay 
RAW 264.7 cells were plated at a density of 30 000/cm2 in 12-well plates. 
After subculturing for 24 h, cells were co-transfected with 0.5 μg of plasmids 
encoding NFAT-luciferase reporter plasmid and 20 ng of Renilla luciferase 
reporter as a control for transfection efficiency. Cells were also transfected 
with 0.5 μg of NFκB- or AP-1 luciferase constructs purchased from 
SABiosciences (Qiagen, Valencia, CA), that were pre-mixed with constitutively 
expressed Renilla luciferase construct at a ratio of 40:1. 48 h after 
transfection, cells were treated with DMSO (vehicle), ICT at doses indicated, or 
10 nM estradiol in DMEM supplemented with 10% charcoal-treated FBS, 
either alone or in combination with 50 ng/ml RANKL. Following indicated 
incubation durations, wells were washed with DPBS and luciferase activity 
was measured using dual luciferase assay system (Promega) according to 
manufacturer’s protocol. Constructs contain either the AP-1 (TGAGTCAG) or 
NFκB (GGGACTTTCC) transcriptional regulatory element sequences that drive 
the expression of the luciferase reporter gene. 
 
3.1.14 Calcineurin-specific phosphatase assay 
RAW 264.7 cells were plated at a density of 30 000/cm2 in six-well plates. 
After subculturing for 24h, cells were treated with DMSO (vehicle), ICT at 
doses indicated, or 10 nM estradiol in DMEM supplemented with 10% 
charcoal-treated FBS, either alone or in combination with 50 ng/ml RANKL. 
 
After the indicated durations, cells were washed with ice cold DPBS and lysed 
with RIPA buffer containing a protease inhibitor cocktail. Calcineurin-specific 




phosphatase activity in cell lysates was measured using a colorimetric assay 
kit (BML-AK816-0001, Enzo Life Sciences, NY, USA). To remove excess 
phosphate as well as nucleotides which are hydrolyzed to release free 
phosphates, cell lysates were passed through a desalting column resin. To 
assess total phosphatase activity, cell lysates were incubated with an assay 
buffer supplemented with Ca2+/calmodulin along with RII phosphopeptide as 
a substrate.  Cell lysates were also incubated with EGTA buffer 
(Ca2+/calmodulin free) and the RII phosphopeptide substrate. Serial dilutions 
of phosphate were used as a standard and total amount of phosphate present 
in each well quantified by measuring absorbance with a microplate reader. 
Calcineurin phosphatase activity was reflected by subtracting amount of 
phosphate present when incubated in EGTA buffer from the total. Calcineurin 
phosphatase activity was normalized against total protein as determined by 
Bradford assay. 
 
3.1.15 Statistical analyses 
All results are expressed as mean ± SEM. Statistical analyses were performed 
using Graphpad Prism 6 (GraphPad Software, Inc., San Diega, CA, USA). 
Statistical differences were assessed by independent t-test for comparison 
between two groups, or one-way ANOVA followed by Tukey’s post hoc 
analysis for multiple comparisons between different groups. Differences were 
considered statistically significant at P < 0.05.  
 




3.2 Animal Experiments 
3.2.1  Establishing the OVX-rat model 
10-12-week old female Sprague-Dawley rats were housed at the Laboratory 
Animal Centre, National University of Singapore. Rats were maintained on a 
minimal isoflavone diet (Teklad Diets, Envigo, NJ, USA) and water ad libitum. 
Following one week’s acclimatization, the rats were divided into 6 groups: (1) 
Pre-treatment sham-operated (Sham-Pre), (2) pre-treatment OVX (OVX-Pre), 
(3) Vehicle-treated sham-operated (Sham-Veh), (4) vehicle-treated OVX (OVX-
Veh), (5) ICT-treated OVX (OVX-ICT) and (6) estradiol valerate-treated OVX 
(OVX-E2). The rats were then subjected to bilateral ovariectomy (OVX) or 
sham surgery. 4 weeks after surgery, Sham-Pre and OVX-Pre rats were 
euthanized while the remaining rats received intraperitoneal injection of 0.9% 
saline (vehicle-treated groups) or ICT solution (40 mg/kg/day), or 
subcutaneously administered estradiol valerate (10 μg/kg/day) 5 times a 
week for 8 weeks. After 8 weeks’ treamtent, rats were euthanized by carbon-
dioxide asphyxiation. Femora, tibiae and the L5 vertebrae were harvested, 
wrapped in 0.9% saline-soaked gauze and stored at -20°C for subsequent 
analyses. The study was reviewed and approved by the Animal Ethics 
Committee at National University of Singapore (protocol R13-4877). 
 
3.2.2  Preparation of treatments 
ICT (> 98% purity) was purchased from Ctech Scientific Pte Ltd (Singapore). 
ICT was dissolved in a mixture solvent containing Kollipher EL: ethanol: PEG 
400: saline (13:7:40:40, v/v). 40 ml of saline was added to 40 ml PEG 400 and 




mixed well. Separately, 13 ml Kolliphor EL was added to 7 ml of 100% ethanol, 
mixed thoroughly and sonicated until resulting solution was clear. ICT was 
dissolved in the Kolliphor EL-ethanol mixture, followed by dropwise addition 
of the saline- PEG 400 mixture. The resulting mixture was mixed well and 
sonicated to ensure complete dissolution of ICT then passed through a 0.2 μm 
filter. ICT solution was prepared to a final concentration of 4 mg/ml. Sufficient 
ICT solution was prepared for a week’s use, aliquoted and stored at -20°C. 
Vehicle-treated rats were given the same Kolliphor EL- ethanol- PEG 400 – 
saline mixture solvent. 
 
β-estradiol 17-valerate was purchased from Sigma (St. Louis, MO, USA) and 
dissolved in sesame oil (3457; Sigma, USA). The resulting solution was 
sonicated then passed through a 0.2 μm filter. Fresh E2 solution was prepared 
every week, to a final concentration of 3 μg/ ml. Sufficient solution was 
prepared for a week’s use, aliquoted and stored at -20°C. 
 
3.2.3  Vaginal smears 
Vaginal smears were taken between 10:00 – 11: 00 hours each day, for 7 days 
before sham surgery or bilateral ovariectomy and for 14 days after. The tip of 
a moistened cotton bud swab was inserted into the vagina, at a 45° angle to 
the rat’s body. Cells from the vaginal lumen and walls were removed by 
rotation of the swab then transferred onto a glass slide. Stage of the estrus 
cycle of each rat was determined by microscopic analysis of the predominant 
cell type in the vaginal smears. Morphology of predominant cell types in the 
stages of the estrus cycle is described in Fig 3.3. 









Figure 3.3 Cytological appearance of vaginal smears from cycling rats 
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3.2.4  Blood sampling and parameters 
Tail blood was obtained to assess estradiol, bone turnover markers 
(osteocalcin, CTx-I) and RANKL concentrations in the serum. In cycling rats, 
blood samples were obtained in the diestrous phase. Serum was collected and 
stored at -80°C. Serum concentrations of estradiol (Enzo Life Sciences, NY, 
USA), osteocalcin (Takara Bio, Shiga, Japan), CTx-I (Cusabio, Wuhan, China) 
and RANKL (R&D systems, Minneapolis, MN, USA) were measured using an 
ELISA kit according to the manufacturer’s instructions. The coefficients of 
variation and sensitivities of the respective ELISA kits are summarized in 
Table 3.1. 
 
Table 3.1. CV and sensitivity of ELISA kits used 
 Intra-CV (%) Inter-CV (%) Sensitivity 
Estradiol  7.16 9.83 14.0 pg/ml 
Osteocalcin 4.48 8.10 0.25 ng/ml 
CTx-I 5.57 11.46 31.25 pg/ml 
RANKL 3.32 6.28 5 pg/ml 
 
 
3.2.5  Micro-computed tomography measurements 
After the rats were euthanized, the right hind leg and lumbar vertebrae were 
excised and stripped of adherent muscles. To facilitate identification, lumbar 
vertebrae were excised together with the lowest rib and pelvis. The right 
femora, femur neck and L5 were scanned ex vivo at a voxel size of 20 μm using 
a microCT system (PerkinElmer Quantum FX, Waltham, MA). 350 slices (7 




mm) were scanned at the region of the distal femur beginning at the growth 
plate and extending proximally along the femur diaphysis. For analysis of the 
trabecular bone, 75 slices (1.5 mm) were selected beginning 0.3 mm from the 
proximal aspect of the growth plate at the distal femora. The entire femur 
neck was scanned with 350 slices and trabecular bone mineral density at the 
femur neck was measured within 100 consecutive slices, with the middle slice 
having the lowest total area in 2D analysis. 350 slices were scanned at the 
region of the L5 vertebrae, for analysis of trabecular bone 100 slices of the 
vertebral body were selected beginning 0.4 mm from the cartilaginous 
endplate. 3D reconstructions and trabecular parameters including trabecular 
bone volume fraction (BV/TV) and trabecular thickness/number/separation 
(Tb.Th, Tb.N, and Tb.Sp) were evaluated using the softwares CTAn and CTVol 
(Bruker SkyScan, Belgium). Bone density was normalized using a phantom 
containing five rods of varying hydroxyapatite densities (QRM GmbH, 
Moehrendorf, Germany).  
 
3.2.6  Mechanical tests 
The mechanical properties of femur neck, femur shaft and L5 were evaluated 
using a materials testing machine (Instron 4465, MA, USA). Prior to 
evaluation, the geometric properties of the specimens were measured using 
digital vernier calipers.  Destructive three-point bend tests were performed at 
the right femur midshaft, using a span length of 15 mm (Fig. 3.4A), with a 
compression rate of 5 mm/min and stabilized with a static preload of 0.5 N.  
 




Following the three-point bend’s test, mechanical properties of the femur neck 
were assessed by a femur neck-bending test. The femur head was mounted in 
dental cement, ensuring that the femur diaphysis is parallel to the loading axis 
(Fig. 3.4B). The load was applied to the top of the femoral head, with static 
preload of 0.3 N and compressed at a rate of 5 mm/ min. 
 
Mechanical properties of the L5 vertebrae were evaluated by a compression 
test. Posterior elements and endplates were removed from the L5 vertebrae 
and specimens were compressed to failure with the loading axis vertically 
aligned to the vertebral body. Vertebrae specimens were stabilized using a 
static preload of 5 N before being loaded to failure at a speed of 2 mm/min.  
 
Load and deformation data for all specimens were collected at 100 Hz using 
the Instron Bluehill software (version 3.0, MA, USA), which computed the 
ultimate load (N), stiffness (N/mm), flexural modulus (N/mm2) and energy to 
failure (mJ) of specimens. The following parameters were then derived as: 
1) Ultimate strength (N/mm2) = ultimate load (N) ÷ cross sectional area 
(mm2); 
2) Elastic modulus (N/mm2) = Stiffness ÷ cross sectional area (mm2) x initial 
length or height of specimen (mm) 
3) Toughness modulus (mJ/ mm3) = energy to failure (mJ) ÷ volume deformed 
(mm3)  










Figure 3.4 Evaluating mechanical properties of rat bone using a materials-
testing machine 
(A) Three-point bend tests at femur midshaft, (B) Femur neck bending test and 
(C) L5 compression test 
A B 
C 




3.2.7  Identification and analysis of circulating osteoclast precursors 
Bone marrow Aspiration 
After the rats were euthanized, the left hind leg was excised and cleaned of 
adherent muscles. Femur and tibiae were separated at the joint and soaked in 
DPBS for 5 minutes. The two ends of the femur and tibiae were excised. A 23-
gauge needle attached to a 5 ml syringe filled with DMEM culture media was 
inserted into the bone. Marrow was then flushed out slowly with DMEM. The 
bones were flushed repeatedly until they appeared pale. Bone marrow cells 
were pelleted by centrifugation at 2000 g for 5 min and resuspended in 10 ml 
DMEM. 30 ml RBC lysis solution (Qiagen, USA) was added to the cell 
suspension and mixed by inverting 10 times. The suspension was incubated at 
room temperature for 5 minutes, then centrifuged at 2000 g for 5 minutes. 
Bone marrow cells were then fixed in 4% paraformaldehyde for subsequent 
analyses of osteoclast precursor populations. 
 
Isolation of PBMC from rats 
The rats were euthanized by carbon dioxide asphyxiation and after confirming 
a lack of toe-pinch reflex, 10 ml of blood was collected by cardiac puncture. 
Blood was diluted in an equal volume of DPBS and layered over Ficoll-paque 
Plus (GE Healthcare, Amersham, UK), then centrifuged at 400 g, 18°C for 30 
minutes with no deceleration. The buffy coat layer was collected, resuspended 
in 5 ml DMEM culture media. 15 ml RBC lysis solution  (Qiagen, USA) was 
added to the cell suspension and mixed by inverting 10 times. The suspension 
was incubated at room temperature for 5 minutes, then centrifuged at 2000 g 




for 5 minutes. PBMC were then fixed in 4% paraformaldehyde for subsequent 
analyses of osteoclast precursor populations. 
 
Identification of osteoclast precursors from rats by cell sorting 
To identify cells with osteoclastogenic potential, bone marrow cells or PBMC 
from 3 rats were pooled. Fixed cells were washed with DPBS, blocked in 3% 
BSA-PBS for 1 hour then stained overnight at 4°C with efluor- conjugated anti-
rat CD11b (Ebiosciences, San Diego, CA, USA) and FITC-conjugated anti-rat Gr-
1 (ab25024; Abcam, Cambridge, UK) antibodies. Cells were washed twice with 
3% BSA-PBS and filtered through a 40 μm pore size filter prior to fluorescence 
assisted cell sorting (Sony Sy3200 Cell Sorter, San Jose, CA, USA). Cell 
populations from the bone marrow and PBMC were collected separately and 
incubated with RANKL and M-CSF (Section 3.1.3) to assess osteoclastogenic 
potential.  
 
For analysis of osteoclast precursor expressions of TRAF6 and NFATc1 
Fixed bone marrow cells or PBMC from rats were washed with DPBS, blocked 
in 3% BSA-PBS for 1 hour then were stained overnight at 4°C with efluor- 
conjugated anti-rat CD11b (Ebiosciences, San Diego, CA, USA) and FITC-
conjugated anti-rat Gr-1 (Abcam, Cambridge, UK) antibodies.  Cells were 
washed thrice with 3% BSA-PBS and permeabilized by incubation in 0.1% 
Triton-X-100 solution for 10 min at room temperature. Cells were washed 
with 3% BSA-PBS and incubated in NFATc1 (sc-13033, Santa Cruz 
Biotechnology) or TRAF6 (sc-7221, Santa Cruz Biotechnology) antibodies for 
2 hours at room temperature, followed by anti-rabbit Alexa Fluor® 594 




antibody (Molecular Probes) for 1 hour at room temperature. Cells were 
washed thrice, filtered through a 40 μm pore size filter and analyzed by BD 
LSRFortessa flow cytometer (BD LSRFortessa, BD Biosciences).  Cd11b+/Gr-1-
/low cells were gated and 10 000 events analysed for fluorescence intensity 
with excitation set at 590 nm and emission at 610 nm. Data collected was 
analyzed with the Summit 4.3 software (Beckman Coulter). 
 
3.2.8  Bone histology 
The left distal femora were fixed in formalin overnight, decalcified in 10% 
EDTA (E5134; Sigma, USA) for 2 weeks (solution was refreshed every 4th day), 
dehydrated and paraffin embedded. Samples were serially sectioned and 
stained with hematoxylin and eosin. 5 μm sections of distal femora were 
stained for TRAP (Sigma, USA) to label osteoclasts. Representative sections 
from 8 rats per group were imaged using a brightfield microscope (Nikon 
Instruments). Histomorphometric analyses for bone surface covered by 
osteoclasts (Oc.S/BS), eroded surface as a ratio to bone surface (ES/BS), and 
number of osteoclasts normalized to bone perimeter (N.OC/B.pm) were 
calculated using ImageJ.  
 
3.2.9  Protein extraction and immunoblot analysis 
After marrow was flushed out, the bones were crushed with a mortar and 
pestle and transferred to a microcentrifuge tube. RIPA lysis buffer (Thermo 
scientific, USA) containing a mini EDTA protease inhibitor cocktail (Roche, 
USA) was added to the bone fragments which were homogenized (Ultra 




Turrax T10 basic homogenizer, IKA, Malaysia) for 3 min at 20 000 rpm. Tools 
were cleaned thoroughly with 70% ethanol to prevent contamination between 
samples.  The homogenized bone in RIPA buffer was then sonicated in a 
biorupter (Bioruptor® Plus, Diagenode, NJ, USA) for 5 cycles (sonication cycle: 
10s on, 10s off) at 4°C. The suspension was centrifuged at maximum speed for 
15 min at 4°C and the supernatant collected.  Bio-Rad Bradford protein assay 
(Bio-Rad Laboratories, Hercules, CA, USA) was used to determine total protein 
concentration with serial dilutions of Bovine Serum Albumin as a standard. 20 
μg of protein lysate in 4x SDS-loading buffer from each treatment group were 
heated at 95°C for 5 minutes. Protein lysates were resolved on SDS-PAGE gel 
using the Mini PROTEAN 3 electropheresis cell (Bio-Rad, USA) and transferred 
onto a nitrocellulose membrane using the semidry transfer method. After 
transfer, nitrocellulose membranes were blocked in 5% non-fat milk (Sigma, 
USA) in PBS for 1 hour. The membranes were then incubated with NFATc1 
(sc-13033, Santa Cruz Biotechnology) or TRAF6 (sc-7221, Santa Cruz 
Biotechnology) antibodies overnight at 4
◦
C. The membranes were washed 3 
times (5 minutes each) with 0.1% Tween 20- PBS (PBST), then incubated with 
either anti-rabbit secondary antibodies conjugated to horseradish peroxidase 
(Dako, USA) at room temperature for 2 h (1: 10 000 dilution in 5% non-fat 
milk). Protein expression signal was detected using Amersham ECL (GE 
Healthcare, Amersham, UK) and the blots were exposed to CL-XPosure Films 
(Thermo scientific, USA). The exposed films were developed using an X-Ray 
Developer (Carestream Health, USA). 
 




3.2.10  Statistical analysis 
All results are expressed as mean ± SEM. Statistical analyses were performed 
using Graphpad Prism 6 (GraphPad Software, Inc., San Diega, CA, USA). 
Statistical differences were assessed by independent t-test for comparison 
between two groups, or one-way ANOVA followed by Tukey’s post hoc 
analysis for multiple comparisons between different groups. Differences were 






CHAPTER 4. RESULTS 
 
4.1 Effect of icaritin on osteoclastogenesis and function in 
vitro 
As reviewed in the introduction, the mouse monocyte cell line, RAW 264.7, 
and human peripheral blood mononuclear cells (PBMC) are well-established 
cell models for studying osteoclastogenesis (Collin-Osdoby & Osdoby, 2012). 
As such, RAW 264.7 cells and human PBMC were chosen to investigate the 
effects of ICT on osteoclastogenesis. Estradiol was used as a positive control as 
its effects on osteoclastogenesis in these models have been studied extensively 






4.1.1 Icaritin inhibited osteoclast formation  
As previously explained, exposure to two cytokines RANKL and M-CSF, is 
essential and sufficient to induce differentiation of the RAW 264.7 cells and 
human PBMC into mature osteoclasts. Compared to undifferentiated 
monocytes, osteoclasts were identified by their multinucleated structure and 
expression of the osteoclast marker, TRAP (Fig. 4.1C, monocytes vs ctrl). In 
both cellular models, the presence of ICT led to a dose-dependent reduction in 
the number of osteoclasts present in the wells. Compared to RANKL-treated 
controls, ICT treatment at 10 nM and 100 nM reduced osteoclast numbers by 
30% and 49% respectively in RAW 264.7 cells, and reduced resultant 
osteoclast numbers by 24% and 40% in human PBMC (P< 0.001) . 
Accordingly, ICT treatment also reduced TRAP activity of cell lysates in a 
concentration-dependent manner. Maximal inhibition in osteoclast formation 
was achieved with 100 nM ICT, which was comparable to the effects of the 









Figure 4.1 Effects of ICT on osteoclast formation in RAW 264.7 cells and human PBMC. 
(A—C) Mouse monocytes (RAW 264.7) and human PBMC were incubated with RANKL and 
M-CSF to induce differentiation into osteoclasts, in the absence or presence of icaritin (ICT) 
at doses indicated, or estradiol (E2, 10nM). The number of TRAP positive (purple cytoplasm) 
multinucleated osteoclasts in each well was counted (scale bar = 200 μm in representative 
images, C), and TRAP enzyme activity in cell lysates measured and expressed as fold change 
compared to control (Ctrl). Data represented as mean ± SEM of 4 independent experiments 






4.1.2 Icaritin inhibited expression of osteoclast-specific genes 
To further ascertain ICT’s effects on osteoclastogenesis, we analyzed the 
expression of osteoclast-specific genes: (1) NFATc1, the master transcription 
factor that mediates osteoclast differentiation, and (2) Cathepsin K, a 
proteolytic enzyme released by mature osteoclasts for bone resorption. 
Quantitative RT-PCR revealed that ICT led to a dose-dependent suppression of 
NFATc1 mRNA expression (Fig. 4.2A, open bars). ICT at doses of 10 nM and 
100 nM reduced NFATc1 mRNA expression by 17.2% and 30.5% respectively, 
compared with RANKL-treated control (P< 0.001).  A similar effect was 
observed for estradiol that inhibited NFATc1 mRNA expression by 34.5%. 
Immunoblot analyses also revealed a dose-dependent inhibition of RANKL-
induced NFATc1 protein expression by ICT (Fig 4.2C). 100 nM ICT inhibited 
NFATc1 protein expression to a similar extent as estradiol. 
 
Similarly, quantitative RT-PCR revealed that ICT led to a dose-dependent 
suppression of Cathepsin K (Ctsk) mRNA expression (Fig 4.2B, open bars). ICT 
at doses of 10 nM and 100 nM reduced Ctsk mRNA expression by 16.8% and 
27.7% respectively, compared with RANKL-treated control (P< 0.001). The 
positive control estradiol suppressed Ctsk mRNA expression by 33.5%.  
Immunoblot analyses revealed a dose-dependent inhibition of RANKL-induced 
Ctsk protein expression by ICT (Fig 4.2D). 100 nM ICT inhibited Ctsk protein 








Figure 4.2 Effects of ICT on expression of osteoclast-specific genes. (A,B) NFATc1 and 
Ctsk gene expression: Total RNA was extracted from cells following exposure to indicated 
treatments for 16h (NFATc1) or 48h (Ctsk), and reverse transcribed to cDNA. Relative gene 
expression was analysed using RT-PCR and normalised to 18s rRNA. Estradiol effects are in 
striped bars. Data expressed as mean ± SEM of 3 independent experiments, expressed as fold 
change relative to RANKL-stimulated controls, *** P < 0.001 vs controls (black bars). (C,D) 
NFATc1 and Ctsk protein expression following the indicated treatments were analysed by 






4.1.3 Icaritin inhibited bone resorption in RAW 264.7 cells and human 
PBMCs 
 
Having shown that ICT inhibits osteoclastogenesis, we then examined the 
effects of ICT on osteoclast resorption. Since 100 nM ICT led to maximal 
inhibition in osteoclast formation, we chose this as our working concentration 
of ICT, and 10 nM estradiol as the positive control.  The actin-bound sealing 
zone is the site of attachment of multinucleated osteoclasts to the bone surface 
within which the osteoclasts maintain a microenvironment necessary to 
resorb bone. We assessed the effect of ICT on sealing zone formation by 
confocal microscopy (Fig. 4.3A). In both cellular models, the presence of ICT 
led to a reduction in the size and number of actin-ring structures, to an extent 
similar to the positive control estradiol. 
 
To assess resorptive function, RAW 264.7 cells and human PBMC were 
cultured on calcium hydroxyapatite-coated multiwell plates in the presence of 
indicated treatments. In both cellular models, ICT led to a dose-dependent 
reduction in osteoclast resorption, as indicated by the total erosion area 
covered by the resorption pits (Fig. 4.3B).  10 nM and 100 nM ICT treatment 
led to a reduction in erosion area by 38.3% and 49.9%, respectively, in RAW 
264.7 cells, and reduced erosion area by 25.6% and 39.7% in human PBMC (P 
< 0.001). The positive control estradiol also led to reductions in erosion area 
by 48.6% and 41.5% in RAW 264.7 cells and human PBMC respectively (P< 
0.001). Notably, 3D measurements (Fig 4.3C) indicate that ICT also reduced 
the volumes of the resorption pits in a concentration-dependent manner 





of resorption pits was observed with 100 nM of ICT, which was similar to the 
effects of estradiol (40.1%). Together, our data suggest that ICT suppressed 
the formation of sealing zones and inhibited resorptive function in both mouse 











Figure 4.3 Effects of ICT on osteoclast function. (A-C) RAW 264.7 cells and PBMC were 
differentiated in the presence of indicated treatments. (A) Representative confocal images show 
multinucleated osteoclasts (blue nuclei) and their actin-bound (red) sealing zones. Actin-rings are 
indicated by white arrowheads, scale bar = 100μm.  (B,C) Cells were differentiated on 
hydroxyapatite-coated wells. Adherent cells were removed and (B) images of resorption pits (area 
in black, scale bar = 500 μm) were acquired by laser microscopy, and area covered by pits 
measured. Data expressed as mean ± SEM of 9 regions (3 regions each in 3 independent 
experiments. (C) Topography of resorption pits was reconstructed in ImageJ and volume of 
resorption pits measured. Data expressed as mean ± SEM of 18 pits (6 pits in each of 3 independent 








4.1.4 Inhibitory effects of icaritin not due to non-specific cytotoxicity 
To determine if the inhibitory effects of icaritin on osteoclast formation and 
function was due to cell toxicity, viability of monocytes (Fig. 4.4A) and 
osteoclast precursors (in presence of RANKL, Fig. 4.4B) was determined by the 
MTS assay. There was no change in viability of both RAW 264.7 cells and 
human PBMC when subjected to ICT at concentrations of 10 and 100 nM (the 
working concentrations used in other experiments) and up to 1000 nM. 
However, there was a 35% decrease in viability at 10 000 nM ICT. Similar 
effects of ICT were observed in the osteoclast precursors (in the presence of 
RANKL), suggesting that the inhibitory effect of ICT on osteoclastogenesis at 





Figure 4.4 Effects of ICT on cell viability. RAW 264.7 cells and PBMC were cultured for 
48 h in the (A) absence (B) or presence of RANKL and indicated doses of ICT. Cell 
viability was determined by MTS assay and expressed as percentage of untreated controls. 






4.1.5 Icaritin does not have effect on mature osteoclasts 
To explore if the reduction in osteoclast numbers with ICT treatment was due 
to its effect on mature osteoclasts, RAW 264.7 cells and human PBMC were 
differentiated in the presence of RANKL and M-CSF, with ICT treatment 
commencing on progressive days: days 0, 1, 2, and 3 in RAW 264.7 cells and 
days 0, 7, 12, and 15 in human PBMCs (Fig. 4.5A). The number of osteoclasts 
formed was quantified after differentiation for 6 (RAW 264.7 cells) or 21 
(human PBMCs) days. Interestingly, ICT inhibited osteoclast formation only 
when added in the early stages osteoclast differentiation (days 0 and 1 for 
RAW 264.7 cells, days 0 and 7 for human PBMCs), but had minimal effects 
when added in the late stages, indicated by resultant osteoclast numbers per 
well (Fig 4.5B,C). 
 
To further ascertain if ICT had effects on mature osteoclasts, RAW 264.7 cells 
were first differentiated in the presence of RANKL and M-CSF for 3 days, by 
which time multinucleated osteoclasts have begun to form, ICT was then 
added to these osteoclast cultures (Fig. 4.5D). Indeed, ICT when added to 
mature osteoclasts did not have effects on sealing zones formed (Fig. 4.5E) or 
resorptive function of the osteoclasts as indicated by area covered by 
resorption pits (Fig. 4.5F). Put together, these results suggest that the 
reduction in osteoclast numbers by ICT was not due to non-specific 
cytotoxicity or its effects on mature osteoclasts, instead, suggesting that ICT 












Figure 4.5 Effects of ICT on mature osteoclasts. (A-C) Cells were differentiated in RANKL and 
MCSF, with ICT (100 nM) treatment commencing on days 0, 1, 2 and 3 for RAW 264.7 cells and 
days 0, 7, 12 and 15 for human PBMCs. (B) TRAP positive multinucleated cells in each well were 
counted, with ICT treatment initiated on the indicated days, and expressed as fold change compared 
to untreated controls. Data expressed as mean ± SEM, n=3, * P < 0.05, *** P < 0.001 vs untreated 
control.  (C) Representative light microscope images of osteoclasts present in each well after ICT 
treatment initiated as indicated, scale bar = 100 μm. (D-F) After 3 days’ incubation in RANKL and 
M-CSF, 100 nM ICT was added to osteoclast cultures for another 3 days. (E) Actin-bound sealing 
zones visualized by confocal microscopy, scale bar = 100 μm and (F) representative laser microscope 
image of well showing area covered by resorption pits in black, scale bar = 500 μm. Experiments 







4.2 Mechanism by which icaritin inhibits osteoclast 
differentiation 
The activation of RANK by its ligand activates several downstream signaling 
cascades, collectively known as the RANKL signaling pathway (Fig 1.5), to 
upregulate the expression of osteoclast-specific genes thereby enabling 
osteoclast differentiation (Boyle et al., 2003). Since ICT has been shown to 
inhibit osteoclast differentiation, we investigated the effects of ICT on the 
RANKL signaling pathway in RAW 264.7 cells.  
 
4.2.1 Effects of icaritin not mediated via estrogen-receptor signaling  
Given that ICT has been shown to exert estrogenic activity in vitro (Tiong et al., 
2012; H. Y. Ye & Lou, 2005) and activation of estrogen receptor (ER)-signaling 
suppresses RANKL-induced AP-1 activity (Shevde, Bendixen, Dienger, & Pike, 
2000), we investigated whether the suppressive effects of ICT on osteoclast 
differentiation were due to activation of ER-signaling. RAW 264.7 cells were 
differentiated in the presence of RANKL and M-CSF, supplemented with ICT or 
estradiol, with and without the ER-antagonist ICI 182 780 (1 μM). Compared 
to vehicle-treated controls, ICT and estradiol treatment inhibited osteoclast 
formation by 35% (P < 0.01) and 45% (P< 0.05) respectively. The presence of 
the ER-antagonist, ICI 182 780, was unable to reverse ICT’s inhibition in 
osteoclast differentiation (Fig 4.6A,B), suggesting that the suppressive effects 





Figure 4.6 Effects of ICT on osteoclast differentiation in presence of ER-antagonist 
RAW 264.7 cells were differentiated for in RANKL and MCSF in the absence (white bars) 
and presence (shaded bars) of ICI 182,780 (1 μM,), supplemented with indicated 
treatments. After 6 days’ treatment, (A) TRAP positive multinucleated cells in each well 
were counted and expressed as fold change compared to untreated controls. Data expressed 
as mean ± SEM, n=3, * P < 0.05, ** P < 0.001 vs untreated control.  (B) Representative 
light microscope images of osteoclasts present in each well after indicated treatments, scale 







4.2.2 Icaritin did not reduce RANK expression of osteoclast precursors 
To study the effect of ICT on the RANKL signaling pathway, we examined the 
effect of ICT on expression of the surface receptor RANK. Expression of RANK 
is regulated by the critical osteoclastogenic cytokine, M-CSF (H. Takayanagi, 
2007). Protein levels of RANK were measured by immunoblotting of whole 
cell lysates (Fig 4.7A). The presence of M-CSF led to an increase in RANK 
protein expression (Fig 4.7A, lanes 1 and 4), while ICT had no effect on RANK 
protein expression in the absence or presence of M-CSF. To further 
corroborate our findings, cell surface expression of RANK was assessed by 
immunofluorescence. Consistently, the presence of M-CSF led to a 30% (P< 
0.001) increase in cell surface expression of RANK (Fig 4.7B). ICT had no effect 
on surface RANK expression in the absence or presence of M-CSF. On the 
contrary, estradiol reduced surface RANK expression by 10.5% (P< 0.05) in 
the absence of M-CSF, and 14.2% (P< 0.001) in the presence of M-CSF, which is 
consistent with previous reports (Galal et al., 2007). These findings suggest 
that ICT action is mediated downstream of RANK, thus we examined the 












Figure 4.7 Effects of ICT on RANK expression. RAW 264.7 cells were cultured for 48 h 
in indicated conditions. (A) RANK protein expression was analyzed by immunoblotting of 
whole cell lysates. β actin was used as a loading control. (B) Cell were fixed and surface 
RANK expression analyzed by confocal microscopy. Data in graph represented as mean ± 
SEM of 3 fields in 3 independent experiments, * p< 0.05, *** p< 0.001 vs matched 
control. Representative confocal images showing surface RANK protein expression 






4.2.3 Icaritin inhibited RANKL-induced NFκB signaling pathway  
Having shown that ICT action is mediated downstream of RANK, we 
investigated the effects of ICT on NFκB-mediated osteoclastogenesis by 
examining RANKL-induced phosphorylation and degradation of the inhibitory 
subunit of NFκB (IκB). Time course analysis showed that RANKL led to 
increased phosphorylation of IκB and a corresponding decrease in total IκB 
levels 15 – 30 min post-stimulation (Fig. 4.8A, upper panels). We therefore 
assessed the effects of ICT on RANKL-induced NFκB pathway at the 30 min 
time-point. Indeed, ICT dose-dependently inhibited IκB phosphorylation and 
prevented its degradation to an extent similar to estradiol (Fig. 4.8B, upper 
panels). The degradation of IκB releases NFκB/p65 thus allowing for its 
phosphorylation and nuclear translocation. Similarly, ICT dose-dependently 
inhibited RANKL-induced phosphorylation of p65 (Fig. 4.8B). Consistent with 
its ability to reverse RANKL-induced IκB degradation, immunoblot analyses of 
cytosolic and nuclear fractions showed that ICT inhibited RANKL-induced 
nuclear translocation of p65 in a dose-dependent manner (Fig. 4.8C). These 
findings were corroborated by immunofluorescence studies. In the absence of 
RANKL, p65 (red) was mostly located in the cytosol, while with RANKL 
stimulation p65 was mostly present in the nucleus (blue). The presence of ICT 
prevented this nuclear translocation (Fig. 4.8D). Estradiol, as a positive control 








We examined the effect of ICT on NFκB transcriptional activity using a 
luciferase reporter gene assay. Indeed, RANKL exposure led to a marked 
increase in NFκB transcriptional activity, which was inhibited by ICT in a 
dose-dependent manner (Fig. 4.8E). Compared to RANKL-stimulated controls, 
100 nM ICT led to a 48.2% reduction in NFκB-dependent luciferase 
expression, while estradiol suppressed NFκB-dependent luciferase expression 
by 36.7%. Collectively, these results suggest that ICT inhibited RANKL-induced 







Figure 4.8 Effects of ICT on RANKL-induced NFκB signaling pathway. (A) RAW 264.7 
cells were incubated with RANKL for indicated durations. Cell lysates were subjected to 
immunoblot analysis with indicated antibodies. (B-D) RAW 264.7 cells were treated with 
indicated doses of ICT or estradiol (E2) for 2h followed by RANKL for 15 min. Cell lysates 
were extracted and subjected to immunoblot analysis with specified antibodies. (B) Dose-
dependent effect of ICT on RANKL-induced activation of NFκB signaling pathway. (C) 
Immunoblot analysis of cytoplasmic (CE) and nuclear (NE) extracts to examine nuclear 
translocation of p65. (D) Representative confocal microscope images of p65 (red) and nuclei 
(blue), scale bar = 20 μm.. (E) NFκB –dependent luciferase reporter gene expression in RAW 
264.7 cells transfected as described in Materials & Methods, stimulated with RANKL for 1h. 
Results normalized to renilla luciferase expression and expressed as fold change compared to 
control. Data in graph represented as mean ± SEM of 3 independent experiments, * P< 0.05, 








4.2.4 Icaritin inhibited RANKL-induced MAPK/AP-1 signaling pathway  
Activation of MAPK, downstream of RANK, induces the expression of NFATc1 
via the AP-1 transcription factor (Boyle et al., 2003; H. Takayanagi, 2007). AP-
1 is a heterodimer of the c-Jun and c-Fos transcription factors that are 
regulated by the c-Jun N-terminal kinase (JNK), p38, and extracellular signal-
regulated kinase (ERK) MAPK (M. Matsumoto et al., 2000; Monje et al., 2005). 
We thus examined the phosphorylation of JNK, p38, and ERK. Consistent with 
previous reports that activation of MAPK following RANKL induction is an 
acute event (Boyle et al., 2003; H. Takayanagi, 2007), we show that maximal 
activation of these MAPK by RANKL was detected at 15 min (Fig. 4.9A). We 
therefore assessed the effect of ICT on MAPK activation following 15 min of 
RANKL exposure. Treatment with ICT significantly decreased phosphorylation 
of JNK, p38 and ERK in a dose-dependent manner (Fig. 4.9B). We examined 
the effect of ICT on AP-1 transcriptional activity using a luciferase reporter 
gene assay. Indeed, RANKL exposure led to a marked increase in AP-1 
transcriptional activity, which was inhibited by ICT in a dose-dependent 
manner (Fig. 4.9C). Compared to RANKL-stimulated controls, 100 nM ICT led 
to a 45.9% reduction in AP-1-dependent luciferase expression, while estradiol 
suppressed AP-1-dependent luciferase expression by 48.1%. The above data 
indicate that anti-osteoclast effects of ICT may be mediated, in part, via the 






  Figure 4.9 Effects of ICT on RANKL-induced MAPK/AP-1 signaling pathway. 
(A) RAW 264.7 cells were incubated with RANKL for indicated durations. Cell 
lysates were subjected to immunoblot analysis with indicated antibodies. (B) Dose-
dependent effect of ICT on MAPK activation: RAW 264.7 cells were treated with 
indicated doses of ICT or estradiol (E2) for 2h followed by RANKL for 15 min. Cell 
lysates were extracted and subjected to immunoblot analysis with specified antibodies. 
(C) AP-1- dependent luciferase reporter gene expression in RAW 264.7 cells 
transfected as described in Materials & Methods, stimulated with RANKL for 1h. 
Results normalized to renilla luciferase expression and expressed as fold change 
compared to control. Data in graph represented as mean ± SEM of 3 independent 






4.2.5 Icaritin suppresses RANKL-induced intracellular ROS production  
Given that the production of intracellular ROS has been shown to play an 
essential role in osteoclast differentiation (M. S. Kim et al., 2010; N. K. Lee et 
al., 2005), we examined the effect of ICT on RANKL-induced intracellular ROS 
production. Intracellular ROS was measured by using the cell permeable dye 
CM-H2DCFHDA, which is highly fluorescent when oxidized. Fluorescence 
intensity was quantified by flow cytometry. Time course analysis revealed that 
RANKL-induced osteoclast differentiation was accompanied by an increase in 
intracellular ROS (Fig. 4.10A,B Control). Intracellular ROS production was 
significantly attenuated by positive controls, ROS scavenger N- Acetyl Cysteine 
(Fig 4.10, NAC, checked bars) and estradiol (Fig 4.10B, striped bars). The 
presence of ICT suppressed RANKL-induced intracellular ROS production in a 
concentration-dependent manner. Compared to RANKL-stimulated controls, 
addition of 10 nM and 100 nM ICT led to a reduction in intracellular ROS by 
16% and 25.7% (Fig. 4.10B). 
 
Since the activation of the NADPH Oxidase 1 (Nox1) enzyme has been shown 
to be responsible for ROS-mediated osteoclast differentiation (M. S. Kim et al., 
2010; Sasaki et al., 2009), we then examined if ICT suppressed ROS production 
by acting on Nox1. Immunoblot analyses showed that ICT attenuated RANKL-
stimulated Nox1 protein levels in a dose-dependent manner (Fig. 4.10C). Since 
GTP-bound Rac1 is a cytosolic component of Nox1 and is required for Nox1 
activation, we examined ICT’s effects on GTP-Rac1 levels as an indicator of 
Nox1 activation. Immunoblot analyses revealed that RANKL enhanced GTP-





effects of RANKL were abrogated by ICT in a dose-dependent manner (Fig. 
4.10C), suggesting that ICT suppressed Nox1 activation. These results indicate 
that ICT may modulate osteoclastogenesis, in part, by inhibiting RANKL-
induced ROS production, through attenuating Nox1 translation and activation. 
 
4.2.6 Icaritin inhibited RANKL-induced TRAF6/cSrc/PI3K signalling 
It has been demonstrated that downstream of TRAF6, the sequential 
activation of tyrosine kinase c-Src and PI3K (Park et al., 2004) is responsible 
for Nox1 activation (N. K. Lee et al., 2005; S. H. Lee & Jang, 2015) and ROS 
production in response to RANKL stimulation, we therefore investigated the 
effect of ICT treatment on this pathway. Immunoblot experiments revealed 
that RANKL led to increased protein levels of TRAF6, c-Src and 
phosphorylated PI3K (Fig 4.10D, lanes 1 and 2). Remarkably, addition of ICT 
dose-dependently decreased RANKL-induced TRAF6 levels, c-Src translation 
and PI3K phosphorylation (Fig. 4.10D). This suggests that the inhibitory effect 
of ICT on ROS production could be mediated through the TRAF6/tyrosine 
kinase c-Src/PI3K pathway. A similar inhibitory effect on TRAF6/c-Src/PI3K 





Figure 4.10 Effects of ICT on RANKL-induced TRAF6/Nox1/ROS signaling (A,B) RAW 
264.7 cells were treated as indicated and intracellular ROS measured by flow cytometry as 
explained in Materials & Methods to determine (A) time course of RANKL-induced 
intracellular ROS production and (B) dose-dependent effect of ICT on intracellular ROS 
(indicated by green fluorescence, insert, scale bar = 100 μm).  Data expressed as mean ± SEM 
of 4 independent experiments, * P< 0.05, ** P< 0.01, *** P< 0.001 vs matched control. (C,D) 
Immunoblot analysis of signaling proteins in the RANKL-induced TRAF6/Nox1/ROS 






4.2.7 Inhibition of ROS-mediated calcineurin phosphatase activity and 
NFATc1 activity  
It has been shown that the RANKL-induced ROS generation leads to the 
dephosphorylation of cytoplasmic NFATc1 (M. S. Kim et al., 2010), allowing its 
nuclear translocation to mediate osteoclastogenesis. The dephosphorylation 
of NFATc1 is also well-known to be dependent on the phosphatase calcineurin 
(H. Takayanagi, 2007). To examine the effect of ICT treatment on calcineurin 
phosphatase activity, we used a calcineurin-specific activity assay kit.  RANKL 
stimulation led to a marked increase in calcineurin-phosphatase activity that 
was dose-dependently attenuated by ICT, in a manner similar to the positive 
controls, estradiol and NAC, the ROS scavenger (Fig. 4.11A). Addition of 10 nM 
and 100 nM ICT inhibited calcineurin activity by 23.1% and 34.7% compared 
to RANKL-stimulated controls. Consistently, the inhibition of calcineurin 
phosphatase activity by ICT was accompanied by increased cytoplasmic levels 
of phosphorylated NFATc1 and suppression in nuclear translocation of 
NFATc1 (Fig. 4.11B, right vs. left). To further corroborate our findings that ICT 
reduces NFATc1 nuclear translocation and activity, we performed an NFATc1-
luciferase reporter gene assay. ICT inhibited NFATc1-dependent luciferase 
expression in a concentration dependent manner (Fig. 4.11C). Compared to 
RANKL-stimulated controls, addition of 10 nM and 100 nM ICT suppressed 
NFATc1-dependent luciferase expression by 25.5% and 39.1%. Put together, 
our data suggest that ICT inhibited RANKL-induced intracellular ROS 
production and consequent calcineurin phosphatase activity to result in 






Figure 4.11 Effects of ICT on NFATc1 nuclear translocation and activity (A) RAW 264.7 
cells were treated as indicated and calcineurin phosphatase activity in cell lysates quantified 
using a calcineurin-specific phosphatase activity assay kit. Data expressed as mean ± SEM of 
3 independent experiments. (B) NFATc1 nuclear translocation: Cell cytosolic (CE) and 
nuclear extracts (NE) were subjected to immunoblot analysis with indicated antibodies. (C) 
NFATc1- dependent luciferase reporter gene expression measured in RAW 264.7 cells 
transfected as described in Materials & Methods, stimulated with RANKL for 24 h. Results 
normalized to renilla luciferase expression and expressed as fold change compared to control. 
Data expressed as mean ± SEM of 3 independent experiments. * P< 0.05, ** P< 0.01, *** P< 





4.2.8 Icaritin mediates proteasomal degradation of TRAF6  
Our data, thus far, suggest that suppression of RANKL-induced NFκB, 
MAPK/AP-1 and ROS signaling pathways led to downregulation of NFATc1 
expression and its transcriptional activity. However, it remained unclear how 
these pleiotropic actions of ICT were derived. Since these effects of ICT were 
not mediated through activation of ER-signaling (Fig. 4.6) and ICT had no 
effects on RANK expression (Fig. 4.7), we hypothesized that the inhibition of 
the various signaling pathways by ICT may act through the RANK adaptor 
protein, TRAF6. As such, we conducted a time course experiment to study the 
levels of TRAF6 in RAW 264.7 cells following RANKL exposure, in the absence 
and presence of ICT.  RANKL stimulation was associated with increased 
TRAF6 protein levels (Fig. 4.12A, left lanes). Notably, treatment with ICT 
inhibited this increase in TRAF6 (Fig. 4.12A, right vs left). Since the presence 
of ICT did not alter TRAF6 mRNA expression (Fig. 4.12B), we hypothesized 
that ICT may exert its effects through degradation of this protein. We 
therefore examined TRAF6 protein levels in the presence of the proteasomal 
inhibitor MG 132. As expected, presence of ICT led to decreased TRAF6 
protein levels (Fig. 4.12C, lanes 1 and 2). Strikingly, MG 132 reversed the 
effects of ICT on TRAF6 levels (Fig. 4.12C), indicating that suppression of 
TRAF6 by ICT was regulated via proteasomal degradation. To further 
corroborate our findings, we differentiated RAW 264.7 cells in the presence of 
ICT and MG 132. Indeed, presence of the MG 132 reversed the suppressive 
effects of ICT on osteoclast differentiation (Fig 4.12D). These results suggest 
that ICT suppressed osteoclastogenesis by mediating proteasomal 






Figure 4.12 ICT mediates proteasomal degradation of TRAF6 (A,B) RAW 264.7 cells 
incubated with RANKL, with or without ICT, for indicated durations. (A) Cell lysates 
subjected to immunoblot analysis with the TRAF6 antibody. (B) TRAF6 gene expression: 
Total RNA was extracted from cells and reverse transcribed to cDNA. Relative gene 
expression was analysed using RT-PCR and normalised to 18s rRNA. Data expressed as 
mean ± SEM. # P< 0.05, ## P< 0.01 vs 0 h control. (C,D) RAW 264.7 cells incubated with 
the proteasomal inhibitor MG132 (1 μM) in the presence or absence of RANKL and ICT: 
(C) Cell lysates were harvested after 48 h treatment and subjected to immunoblot analysis 
performed with TRAF6 antibody, and (D) number of TRAP positive (purple cytoplasm) 
multinucleated osteoclasts in each well was counted after 6 days’ treamtent, with 
corresponding representative images, scale bar = 100 μm. Data in graph represented as 






4.2.9 Icaritin and TRAF6 ubiquitination 
The degradation of intracellular proteins by the proteasome is a specific and 
regulated process. This specificity is ensured by attaching a small protein tag 
(ubiquitin) to mark the proteins for destruction by the 26S proteasome 
(Glickman & Ciechanover, 2002; Lim & Lim, 2011).  Having shown that ICT 
mediates proteasomal degradation of TRAF6 in the presence of RANKL, we 
then examined the effect of ICT on ubiquitination of TRAF6. TRAF6 was pulled 
down by immunoprecipitation and subjected to immunoblot analyses which 
showed that in the absence of RANKL, ICT did not lead to significant changes 
in ubiquitination of TRAF6 (Fig 4.13A, lanes 1 and 3). However, in the 
presence of RANKL, ICT treatment led to a significant increase in TRAF6 
ubiquitination (Fig 4.13A, lanes 2 and 4). Lysine 48-linked polyubiquitin 
chains is a well-regarded tag to direct proteins for proteasomal degradation 
(Mallette & Richard, 2012; Thrower, Hoffman, Rechsteiner, & Pickart, 2000), 
we therefore examined lysine 48-linked polyubiquitination of TRAF6. In the 
absence of RANKL, ICT did not lead to significant changes in lysine 48- 
polyubiquitination of TRAF6. However, in the presence of RANKL, ICT 
treatment led to a significant increase in TRAF6 lysine 48- polyubiquitination. 
These results suggest that indeed, ICT mediates proteasomal degradation of 
TRAF6 via the ubiquitin-proteasome pathway. Overall, our cellular data 
suggest that ICT suppressed osteoclastogenesis by regulating proteasomal 
degradation of the critical adaptor protein TRAF6; thereby inhibiting 







  Figure 4.13 Effects of ICT on ubiquitnation of TRAF6. RAW 264.7 cells in the 
presence or absence of RANKL and ICT for 24 h and immunoprecipitation was carried out 







4.3 Effects of icaritin in the OVX rat model 
As outlined in the introduction, the ovariectomized (OVX) rat is an excellent 
preclinical animal model as it emulates important clinical features of estrogen 
deficiency-induced osteoporosis in the human skeleton, resulting in rapid loss 
in cancellous bone mass and strength (Kimmel, 1996; Thompson et al., 1995). 
Given the promising properties of ICT demonstrated in the cellular models, we 
employed the OVX rat model to investigate the potential therapeutic effects of 
ICT on treating estrogen deficiency-mediated osteoporosis and to corroborate 
our in vitro findings in an animal model. 
 
It has been reported that intraperitoneal administration of ICT to adult female 
Sprague Dawley rats at doses of 20, 40 and 60 mg/kg led to a dose-dependent 
increase in concentrations of ICT detected in blood plasma (Zhang, 2014). It 
was demonstrated that at a dose of 40 mg/kg, a maximum concentration of ~ 
1.5 μM ICT was detected in the blood plasma and ≥ 700 nM ICT was detected 
in the plasma for up to 8 h post administration. Similarly, our group previously 
reported that intraperitoneal administration of 40 mg/kg ICT to SCID mice 
induced a rapid rise in serum concentrations of ICT, which reached a 
maximum of ~ 5 μM (Sun et al., 2015). Additionally, we showed that serum 
concentrations of ICT remained well within levels of ICT shown to inhibit 
osteoclastogenesis (Fig. 4.1) for up to 9 h post-adminstration As such, 
intraperitoneal administration of ICT at 40 mg/kg/day was chosen for our 






Figure 4.14 Establishing the OVX rat model based on (A) Oestrous cycles of rats 
3 weeks after sham surgery or bilateral ovariectomy. Three representative rats from 
each group are presented. P, proestrus; E, oestrus; M, metoestrus; D, dioestrus. (B) 
Serum estradiol (E2) levels measured by ELISA. Data represented as mean ± 
SEM, n=8. a p< 0.01 vs baseline Sham-Veh. 
4.3.1 To establish and validate the OVX-rat model 
To ascertain completeness of bilateral ovariectomy, the oestrus cycles of rats 
were monitored for 3 weeks, beginning 1 week post-ovariectomy. Sham-
operated rats had a normal oestrus cycle of 4-5 days, while OVX rats were 
acyclic and remained in the diestrus phase (Fig 4.14A). Additionally, serum 
estradiol levels of the OVX rats were significantly lower than that of sham-
operated counterparts (P < 0.05), indicating that OVX rats were in a state of 
estrogen-deficiency.  Put together, these results suggest that bilateral 









4.3.2 Icaritin treatment prevented OVX-induced deterioration in bone 
architecture 
To examine the effects of ICT treatment on bone architecture, the femora (Fig. 
4.15) and 5th lumbar vertebrae (Fig. 4.16) of rats were subjected to MicroCT 
imaging and subsequent histomorphometric analysis. Analysis of baseline 
controls (Sham-pre and OVX-pre) show that ovariectomy resulted in marked 
decrease in trabecular bone volume (BV/TV, P< 0.01) and trabecular number 
(Tb.N, P< 0.001). Accordingly, there was a marked increase in trabecular 
spacing (Tb.Sp, P< 0.01) of the OVX-pre rats compared with Sham-pre, 
indicating an increase in trabecular porosity. A drastic decrease in bone 
mineral density (BMD) of OVX-pre rats compared to Sham-pre was detected at 
the (Fig 4.15E) and L5 vertebral body (Fig. 4.16E). The deterioration in bone 
microarchitecture as well as the decrease in BMD validates our OVX-induced 
osteoporosis model. 
 
Analysis of the trabecular parameters shows a further deterioration in 
trabecular architecture of the vehicle-treated OVX rats (OVX-Veh) compared 
to OVX-pre rats. Treatment with ICT (OVX-ICT) prevented OVX-induced 
deterioration in bone architecture such that BV/TV, Tb.N and Tb.Sp were non-
significantly different from that of OVX-pre. These effects of ICT were 
consistently demonstrated in both the femora and L5 vertebrae. There was a 
drastic decrease in BMD measured at the femoral neck (Fig 4.15E) and L5 
vertebral body (Fig. 4.16E) of the vehicle-treated OVX rats compared with 
Sham-Veh rats. Notably, treatment with ICT prevented this decrease in BMD to 





bone-protective effects were observed in OVX rats treated with the positive 
control, estradiol (OVX-E2). Histological analysis of the distal femur also 
revealed similar findings in trabecular bone architecture, where ovariectomy 
resulted in decreased trabecular number and density, with increased 
trabecular spacing compared to sham-operated controls (Fig. 4.15F, Sham-Veh 
vs OVX-Veh). Treatment with ICT and the positive control, E2, prevented this 
deterioration in trabecular architecture. Additionally, H&E-stained histological 
sections of the distal femur showed that there was a significant increase in 
marrow adiposity of OVX-Veh rats compared with Sham-Veh, which was 










Figure 4.15 Effects of ICT on trabeculae of the distal femur (A) Representative 
microCT reconstructions of trabecular bone in distal femur, scale bar = 1mm. (B) Bone 
volume/ total volume (BV/TV), (C) trabecular number (Tb.N) and (D) trabecular space 
(Tb.Sp), and (E) Bone mineral density (BMD) of femur were analyzed with the CTan 
software. Data in graphs represented as mean ± SEM (n=8). a P< 0.05, b P< 0.01, c P< 
0.001 vs OVX-pre; * P< 0.05, ** P< 0.01, *** P  0.001 vs OVX-Veh. (F) Representative 










Figure 4.16 Effects of ICT on trabeculae of the 5th lumbar vertebrae (A) 
Representative microCT reconstructions of trabecular bone in L5, scale bar = 1 
mm. (B) Bone volume/ total volume (BV/TV), (C) trabecular number (Tb.N) and 
(D) trabecular space (Tb.Sp), and (E) Bone mineral density (BMD) of L5 were 
analyzed with the CTan software. Data in graphs represented as mean ± SEM 
(n=8). a P< 0.05, b P< 0.01, c P< 0.001 vs OVX-pre; * P< 0.05, ** P< 0.01, *** 






4.3.3 Icaritin treatment prevented OVX-induced decline in bone 
strength 
Osteoporosis is characterized by a decline in bone strength that results from 
the deterioration in bone architecture and decreased bone mineral density 
(Ammann & Rizzoli, 2003). To assess the effects of ICT on OVX-induced 
changes in bone strength, the mechanical properties of the femur neck (Fig 
4.17A), femur shaft (Fig 4.17B) and L5 vertebral body (Fig 4.17C) were 
evaluated by loading these bones to failure using a materials testing machine. 
Mechanical properties evaluated include ultimate strength, the maximum 
force per unit area the bones can withstand before fracturing; stiffness, which 
reflects the rigidity of the bones as it measures the extent to which the bones 
resist deformation in response to an applied force; and energy to failure, a 
measure of the amount of energy the bone absorbs before fracturing. Analyses 
of baseline controls revealed that ovariectomy led to deterioration in 
mechanical properties of the femur neck, femur shaft and L5 vertebrae (Fig 
4.17A-C, Sham-pre vs OVX-pre). Further deterioration in these mechanical 
properties was detected in the vehicle-treated OVX rats (Fig 4.17A-C, OVX-pre 
vs OVX-Veh), and this deterioration was prevented by ICT treatment, such that 
ultimate strength, stiffness and energy to failure of these bones were non-
significantly different from that in OVX-pre rats. Estradiol treatment also 
prevented deterioration in mechanical properties of the femur neck, femur 
shaft and L5. In this study, energy to failure of bones was used as an indicator 
of the fracture toughness or resistance of the bone to fracture in terms of work 





these bones are consistent with the quality of bones (bone architecture and 




Figure 4.17 Effects of ICT on mechanical properties of bone. Ultimate strength, modulus 
and energy to failure of (A) femur neck, (B) femur shaft and (C) L5 vertebrae were evaluated 
using a materials testing machine. Data in graphs represented as mean ± SEM (n=8). a P< 0.05 






4.3.4 Icaritin treatment suppressed osteoclast formation and 
resorption in vivo 
 
It is well established that increased osteoclast formation and activity is pivotal 
to the pathogenesis of estrogen deficiency-mediated osteoporosis (Khosla et 
al., 2012). To investigate the effect of ICT on osteoclastogenesis in vivo, 
histologic sections of the distal femur were stained for the osteoclast marker, 
TRAP. The distal femur is a region rich in trabecular bone, the site of active 
bone remodeling. Analysis of baseline controls showed that there was a 
significant increase in the area covered by osteoclasts (identified by purple 
TRAP stain) in OVX-pre rats compared with Sham-pre. Indeed, there was a 
further increase in area covered by osteoclasts in vehicle-treated OVX rats 
compared with OVX-pre (Fig 4.15A). Correspondingly, surface measurements 
from the TRAP-stained sections revealed that ICT treatment decreased 
osteoclast-covered surface (Oc.S/BS) by 58.4%, reduced eroded surface 
(ES/BS) by 62.7% and reduced osteoclast numbers (N.OC/B.PM) by 44.9% 
compared to OVX-Veh (Fig. 4.15B). This reduction in osteoclast-covered 
surface, eroded surface and osteoclast numbers to levels similar to that of 
OVX-pre suggests that ICT abrogated OVX-induced osteoclast formation and 
activity.  
 
C-terminal telopeptide 1 (CTX-I) is a degraded fragment of collagen type-1 
that is generated during bone resorption (Henriksen et al., 2007). Thus, we 
assessed osteoclast activity by measuring serum levels of this bone resorption 
marker, CTX-I. Ovariectomy resulted in a ~2 fold increase in serum levels of 





Veh). There was a 36% decrease in serum levels of CTX-I in ICT-treated rats 
compared with OVX-Veh (P< 0.01), further supporting ICT inhibition of OVX-
induced osteoclast activity in vivo (Fig. 4.15C).  
 
Osteocalcin is a noncollagenous protein produced specifically by osteoblastic 
cells for deposition in the bone matrix (Patti, Gennari, Merlotti, Dotta, & Nuti, 
2013) and is therefore used as a biochemical marker of bone formation. 
Ovariectomy resulted in a significant decrease in serum levels of osteocalcin at 
baseline (Fig 4.17D, Sham-pre vs OVX-pre). Interestingly, a small but non-
significant increase in serum levels of osteocalcin was detected in OVX-Veh 
rats compared with OVX-pre, which could be attributed to an increase in bone 
remodeling. Compared with OVX-pre, treatment with ICT led to a ~70% 
increase (P< 0.01) in serum levels of osteocalcin.  
 
Estradiol, as the positive control, exhibited a similar inhibitory effect on 
osteoclast formation and activity in vivo, and decreased Oc.S/BS by 47%, 
reduced ES/BS by 64.8% and reduced osteoclast numbers (N.OC/B.PM) by 
44.2% compared to OVX-Veh (Fig. 4.15B). There was a 57.7% decrease in 
serum levels of CTX-I in OVX-E2 rats compared to OVX-Veh rats.  It is 
noteworthy that although ICT and E2 led to similar inhibitory effects on 
osteoclastogenesis and activity in the OVX rats, the effects of ICT are not 






  Figure 4.17 Effects of ICT on osteoclast formation and activity in vivo (A) Representative 
TRAP-stained histologic sections of distal femora showing effects on osteoclast (purple-
stained area) numbers, scale bar = 200 μm. (B) Fold change in osteoclast surface/ bone 
surface (Oc.S/ BS), number of osteoclasts/ bone perimeter (N.Oc/ B.Pm), and eroded surface/ 
bone surface (ES/BS) based on analysis of TRAP-stained histologic sections. (C) Serum 
concentrations of CTx-I and osteocalcin quantified by ELISA. Data in graphs represented as 
mean ± SEM (n=8). a P< 0.05, b P< 0.01, c P< 0.001 vs OVX-pre* P < 0.05, ** P < 0.01, *** 






4.3.5 Icaritin treatment suppressed TRAF6 protein expression  
Since we have demonstrated in our cellular studies that ICT suppressed 
osteoclastogenesis by regulating proteasomal degradation of the critical 
adaptor protein TRAF6 (section 4.2.8), we sought to study TRAF6 protein 
expression in the OVX rat model by examining TRAF6 protein expression in 
the circulating osteoclast precursors. 
 
Identifying osteoclast precursor population in peripheral blood mononuclear 
cells & bone marrow 
To ascertain the osteoclastogeneic potential of cell populations present in the 
peripheral blood and bone marrow, PBMC and bone marrow cells were 
separately harvested from 3 rats, pooled, and stained for the cell surface 
markers CD11b and granulocyte receptor-1 (Gr-1). Using fluorescence-
assisted cell sorting, cell populations were collected separately then cultured 
in the presence of RANKL and M-CSF. We demonstrated that in both the blood 
and bone marrow, Cd11b+/Gr-1-/low cells differentiated into multinucleated 
TRAP-positive cells (Fig 4.16, R2). The Cd11b+/Gr-1hi cells (Fig. 4.16, R3) 
isolated from the bone marrow but not the blood were able to differentiate 
into multinucleated cells, while Cd11b-/Gr-1-/low cells (Fig. 4.16, R4) from both 
the blood and bone marrow showed no osteoclastogenic potential. These 
findings are consistent with previous reports demonstrating that Cd11b and 
Gr-1 are cell surface markers expressed on circulating osteoclast precursors 
(Z. Yao et al., 2006). We therefore identified Cd11b+/Gr-1-/low cells as 





 Figure 4.18 Identification of cell populations with osteoclastogenic potential from 
peripheral blood and bone marrow cells. (A) PBMC or (B) bone marrow cells pooled 
from 3 rats were stained with anti-CD11b and anti-Gr-1 antibodies and subjected to FACS 
analysis. Live cells were gated using forward and side scatter (R1). CD11b+/Gr-1-/low  (R2), 
CD11b+/Gr-1hi (R3), and CD11b-/Gr-1- (R4) populations were collected separately and 
cultured with M-CSF and RANKL to generate osteoclasts. Representative light microscope 
images of TRAP-positive osteoclasts formed from the respective populations of the PBMC 






Icaritin treatment suppressed TRAF6 protein expression in circulating 
osteoclast precursors 
To study the effect of ICT treatment on osteoclast precursors, blood and bone 
marrow cells from rats were stained for Cd11b and Gr-1 surface markers and 
analyzed by flow-cytometry, where Cd11b+/Gr-1-/low cells were gated and 
expression of TRAF6 quantified. Interestingly, analysis of circulating 
osteoclast precursors showed that ovariectomy led to 90% increase in TRAF6 
expression in Cd11b+/Gr-1-/low PBMCs (P< 0.001) and 50% in TRAF6 
expression in  Cd11b+/Gr-1-/low bone marrow cells (P< 0.01) (Fig 4.19A,B).  
Compared with OVX-Veh rats, treatment with ICT (Fig. 4.19A,B, open bars) led 
to a 25.8% and 16.6% reduction in TRAF6 protein levels in the osteoclast 
precursors present in PBMC (P< 0.001) and bone marrow cells (P< 0.05), 
respectively. Estradiol treatment also led to a 20.5% and 18.8% suppression 
in TRAF6 expression in the osteoclast precursors present in PBMC (P< 0.01) 
and bone marrow cells (P< 0.05), respectively. These results showed that ICT 
treatment suppressed OVX-induced TRAF6 protein expression in the 







Figure 4.19 Effect of ICT on TRAF6 protein expression in osteoclast precursors. 
Rat (A) PBMC and (B) bone marrow cells were labeled with Cd11b and Gr-1 




) were gated and analyzed by 





cells in (A) PBMC and (B) bone marrow were analyzed. Results expressed as fold 
change with respect to sham-operated controls (Sham-Veh). Data expressed as mean ± 
SEM of 8 rats per group. (A) Histogram shows representative distribution of PE- 
labeled TRAF6 protein in 10,000 osteoclast precursors (from PBMC) of an animal in 






Icaritin treatment suppressed TRAF6 protein expression in bone 
To assess the effect of ICT on TRAF6 protein expression in the bone, tibial 
bone lysates were subjected to immunoblot analysis (Fig. 4.18A,B). 
Ovariectomy led to a drastic increase in TRAF6 protein expression (~ 9.5 
folds, P< 0.01) in the bone compared with sham-operated controls. Compared 
to OVX-Veh controls, ICT treatment reduced TRAF6 protein expression by 
80% (P< 0.01).  Estradiol reduced TRAF6 protein levels in the bone by 76.1% 
compared with OVX-Veh rats (P< 0.05). These results corroborate our findings 




Figure 4.20 Effect of ICT on TRAF6 protein levels in the bone. (A) Immunoblot 
analysis of TRAF6 protein expression in tibial bone tissue from 3 representative rats 
per group and (B) corresponding densitometry analysis. Data are expressed as mean ± 






4.3.6 Icaritin treatment suppressed NFATc1 protein expression  
Given our in vitro findings that ICT treatment suppressed osteoclast formation 
and resorption, and downregulated the expression and activity of NFATc1, the 
master transcription factor regulating osteoclastogenesis, we sought to 
determine whether ICT resulted in similar effects on NFATc1 in the OVX rats.  
 
 
Icaritin treatment suppressed NFATc1 protein expression in circulating 
osteoclast precursors 
To study the effect of ICT treatment on osteoclast precursors, blood and bone 
marrow cells from rats were stained for Cd11b and Gr-1 surface markers and 
analyzed by flow-cytometry, where Cd11b+/Gr-1-/low cells were gated and 
expression of NFATc1 quantified. Analysis of circulating osteoclast precursors 
showed that ovariectomy led to 37.7% increase in TRAF6 expression in 
Cd11b+/Gr-1-/low PBMCs (P< 0.05) and 22% in TRAF6 expression in  
Cd11b+/Gr-1-/low bone marrow cells (P< 0.05) (Fig 4.21A,B).  Compared with 
OVX-Veh rats, treatment with ICT (Fig. 4.21A,B, open bars) led to a 34.2% and 
23.5% reduction in TRAF6 protein levels in the osteoclast precursors present 
in PBMC (P< 0.05) and bone marrow cells (P< 0.01), respectively. Estradiol 
treatment also led to a 25.2% and 15% suppression in TRAF6 expression in 
the osteoclast precursors present in PBMC (P< 0.05) and bone marrow cells 
(P< 0.05), respectively. These results showed that ICT treatment suppressed 






Icaritin treatment suppressed NFATc1 protein expression in bone 
To assess the effect of ICT on NFATc1 protein expression in the bone, tibial 
bone lysates were subjected to immunoblot analysis (Fig. 4.21C,D). 
Ovariectomy led to a significant increase (~14 folds, P< 0.05) in NFATc1 
protein expression in the bone compared with sham-operated controls. Both 
ICT (P< 0.01) and estradiol (P< 0.05) treatments reduced NFATc1 protein 
expression to levels similar to that of sham-operated controls. These results 
show that ICT treatment suppressed NFATc1 protein expression in vivo.  
  Figure 4.21 Effect of ICT on NFATc1 protein expression in OVX rats. Rat (A) PBMC 





) were gated and analyzed by flow cytometry. Mean 




 cells from (A) PBMC 
and (B) bone marrow were analyzed. Results expressed as fold change with respect to 
sham-operated controls (Sham-Veh). (C) Immunoblot analysis of NFATc1 protein 
expression in tibial bone tissue from 3 representative rats per group and (D) corresponding 
densitometry analysis.  Data expressed as mean ± SEM, * P< 0.05, ** P< 0.01, *** P < 






4.3.7 Icaritin treatment did not lead to changes in RANKL levels 
To investigate whether ICT treatment downregulated RANKL levels leading to 
its consequential suppression of osteoclast numbers and activity, we analyzed 
serum RANKL concentrations in our animal model in response to ICT. 
Consistent with previous reports (Ominsky et al., 2008), ovariectomy led to a 
2 fold increase (P< 0.01) in serum levels of RANKL compared to sham-
operated rats (Fig. 4.22, baseline: Sham-Veh vs OVX rats). After 8 weeks’ 
treatment, ICT did not lead to significant changes in RANKL levels compared 
to vehicle-treated OVX controls (Fig 4.22, OVX-Veh vs OVX-ICT). In contrast, 
estradiol treatment led to a 10% decrease (P< 0.01) in serum levels of RANKL 
(Fig 4.22, OVX-Veh vs OVX-E2).  These results show that ICT suppression of 
OVX-induced osteoclastogenesis and osteoclast resorption was independent of 
its effects on RANKL.   
  
Figure 4.22 Serum estradiol levels of rats measured at baseline: 4 weeks after 
sham surgery or bilatery OVX, or post-treatment: after 8 weeks treatment.  
Serum RANKL levels measured by ELISA. Data represented as mean ± SEM, 
n=8 rats per group. a p< 0.01 vs baseline Sham-Veh; b p< 0.01 vs post-treatment 






4.3.8 Icaritin treatment has favourable short-term safety profile in OVX 
rats 
 
Icaritin treatment did not lead to significant changes in body weight of rats 
The body weight of rats can be used as a clinical sign of morbidity if the 
decrease in body weight is > 20% from baseline or rapid weight loss (>10% 
body weight) occurs within a week (Foltz & Ullman-Cullere, 1999). Body 
weight of the rats was thus measured weekly as the animals received 
treatment. While ovariectomy led to a signficant increase in bodyweight of 
rats compared to sham-operated controls (Fig 4.23A, Week 4: Sham-Veh vs 
OVX rats). There was no significant change in the bodyweight of ICT-treated 
rats over the 8 weeks of treatment (Fig 4.23A, Weeks 4-12). 
 
Icaritin treatment did not lead to uterine hypertrophy of rats 
ICT has been shown to exhibit estrogenic activity in vitro leading to the 
proliferation of the MCF-7 breast cancer cells (Tiong et al., 2012), and it is 
well-established that estrogen leads to uterine hypertrophy substantially 
increasing the risks of endometrial cancer (Knowler, 1983; Million Women 
Study), we therefore examined the effects ICT of uterine weight in the OVX rat 
model (Fig. 4.23B,C). Indeed, ovariectomy led to a drastic decrease in uterine 
weight compared with sham-operated controls (Sham-Veh vs OVX-Veh). 
Compared to OVX-Veh rats, ICT treatment did not lead to significant changes 
in uterine weight while estradiol treatment resulted in ~ 4 folds increase in 
uterine weight of the OVX-rats (Fig 4.23B, OVX-Veh vs OVX-E2), which was 
significantly higher than that of sham controls (P< 0.01). ICT treatment also 





compared with vehicle-treated OVX rats (Fig 4.23D). Put together, these 
results support our in vitro findings that ICT did not inhibit osteoclastogenesis 
via the ER-signaling. Additionally, unlike estradiol, ICT did not lead to uterine 
hypertrophy suggesting that ICT treatment may not result in the same 

















Figure 4.23 Effect of ICT on body weight and uterine weight of OVX rats. (A) Body weight of 
rats measured weekly. Data represented as mean ± SEM, n=8 rats per group, * P < 0.01 vs 
time-matched OVX-Veh. (B,C) Uteri of rats were harvested at termination, surrounding fat 
tissue removed and weighed. Data represented as mean ± SEM, n=8 rats per group. a P < 0.05, 
b P < 0.01 vs Sham-Veh; *** p< 0.001 vs OVX-Veh. (D) Serum estradiol levels measured by 
ELISA. Data represented as mean ± SEM, n=8. a P < 0.01 vs baseline Sham-Veh; b  P< 0.001 





CHAPTER 5. DISCUSSION 
 
In this thesis, we present the novel finding that proteasome-mediated 
degradation of the adaptor protein TRAF6 mediates the anti-osteoporotic 
effects of icaritin. We show that icaritin suppresses osteoclastogenesis and 
osteoclast function both in vitro and in vivo, thereby preventing estrogen 
deficiency-mediated osteoporosis. The mechanism(s) by which icaritin 
inhibits osteoclast differentiation was investigated in vitro and in an OVX rat 
model. ICT reduced TRAF6 protein expression, thereby inhibiting 
RANKL/RANK activation of downstream NFκB, MAPK/AP-1 and ROS signaling 
pathways in the RAW 264.7 osteoclast precursor cell model. Ultimately, 
suppression of TRAF6-mediated pathways reduced the expression and 
activity of the key osteoclastogenic transcription factor NFATc1 (Fig 5.1). 
Similarly in estrogen-deficient rats, maintenance of bone mass, strength and 
suppression of bone resorption by ICT was associated with reduction in 
TRAF6 and NFATc1 protein expression in osteoclast precursor macrophages. 
Taken together, the findings of this thesis uncover the clinical potential of 
icaritin as an anti-osteoporotic agent, and points to TRAF6 adaptor protein as 






Figure 5.1 Schematic model: ICT induced TRAF6 degradation results in inhibition of 
NFATc1 expression and activity. Hypothesized mechanism by which ICT inhibits 
osteoclastogenesis. Activation of RANK by its ligand induces NFATc1 gene expression and 
activity through NFkB/p65 and MAPK/AP-1 signaling pathways and calcineurin activation, 
thereby upregulating osteoclast-specific genes. ICT mediates proteasomal degradation of 
TRAF6, thus blocking RANKL-induced activation of the downstream signaling pathways, 





5.1 Effects of icaritin on osteoclastogenesis 
5.1.1 Icaritin inhibits osteoclast differentiation  
As previously outlined, osteoclastogenesis can be broadly divided into three 
stages: the commitment of monocyte/ macrophages into osteoclast precursors 
and their proliferation, fusion of the osteoclast precursors to form mature 
multinucleated osteoclasts, followed by activation of these osteoclasts to 
resorb bone (Soysa et al., 2012; Takayanagi, 2007).  Given that ICT suppressed 
osteoclast formation and inhibited the expression of osteoclast-specific genes, 
we sought to determine if this was due to ICT effects on the osteoclast 
precursors. The viability of monocytes and osteoclast precursors (in the 
presence of RANKL) was not inhibited at doses of ICT that suppressed 
osteoclastogenesis, indicating that the reduction in osteoclast numbers was 
not due to non-specific cytotoxicity. Additionally, ICT did not affect sealing 
zone formation or resorptive capacity of mature osteoclasts, suggesting that 
ICT could act to inhibit the commitment and differentiation of osteoclast 
precursors into mature multinucleated osteoclasts. These findings set the anti-
osteoclast effects of ICT apart from that of bisphosphonates, whose effects are 
exerted on mature osteoclasts leading to osteoclast inactivation and apoptosis 
(Hughes et al., 1995; Matsumoto et al., 2000; Reszka & Rodan, 2003). Given 
that ICT did not reduce viability of the osteoclast precursors nor exert effects 
on mature osteoclasts, coupled with the reduction in expression of NFATc1, 
the master transcriptional regulator of osteoclast differentiation, suggest that 






5.2 Mechanism by which icaritin inhibits osteoclast 
differentiation 
 
5.2.1 Icaritin inhibited NFATc1 expression via NFκB and MAPK/AP-1 
pathways 
The importance of the NFκB family of dimeric transcription factors to 
osteoclastogenesis was revealed when deletion of the NFκB1/p50 and 
NFκB2/p52 subunits led to severe osteopetrosis in mice as a result of 
osteoclast deficiency (Iotsova et al., 1997; Monje et al., 2005).  It has since 
been well established that RANKL, after binding to its cognate receptor, 
triggers the canonical NFκB pathway by activating the IKK complex, resulting 
in the phosphorylation and degradation of IκB to release the p50-p65 dimer 
for nuclear translocation (Soysa & Alles, 2009). While RANKL has also been 
shown to activate the alternative NFκB pathway by triggering the NFκB-
inducing kinase leading to the eventual generation of the p52-RelB dimer 
(Novack et al., 2003), it remains unclear which of the two NFκB pathways are 
dominant in osteoclast differentiation. Nonetheless, Asagiri et al. (2005) have 
shown that the p50-p65 subunits are recruited to the NFATc1 promoter 
following RANKL stimulation, indicating that these NFκB components are 
crucial in regulating the expression of NFATc1. In this thesis, we present 
substantial evidence to show that icaritin downregulates NFATc1 expression 
by inhibition of the RANKL-induced canonical NFκB pathway that resulted in 







In addition to the NFκB pathway, c-Fos, a member of the AP-1 family of 
transcription factors, has also been shown to be indispensable for osteoclast 
differentiation given the osteopetrotic phenotype of c-Fos knockout mice 
(Wang et al., 1992). It was further delineated that c-Fos is crucial to the 
induction of NFATc1 since recruitment of c-Fos to the NFATc1 promoter has 
also been demonstrated. Additionally, induction of NFATc1 mRNA by RANKL 
is abrogated in c-Fos deficient cells (Asagiri et al., 2005; Iotsova et al., 1997).  
Given that c-Fos can only heterodimerize with members of the Jun family to 
form the AP-1 heterodimer, Soysa and Alles (2009) demonstration that 
expression of NFATc1 is Fos/Jun dependent is in keeping with the presence of 
AP-1 response elements in the NFATc1 promoter (Asagiri et al., 2005). As 
explained in the introduction, the expression and activity of the AP-1 
transcription factor is regulated by the mitogen-activated protein kinases JNK, 
ERK and p38 (Monje et al., 2005; Novack et al., 2003). Indeed, we have shown 
in this thesis that RANKL induces activation of the JNK, ERP and p38 MAPKs 
that was inhibited by icaritin treatment and correspondingly, icaritin 
downregulated AP-1 transcriptional activity. Put together, our results 
therefore suggest that icaritin’s inhibition of NFATc1 expression is dependent 







5.2.2 Icaritin inhibits NFATc1 nuclear translocation and transcriptional 
activity by suppressing the TRAF6/cSrc/Nox1 pathway 
There has been a recent accumulation of evidence supporting the importance 
of intracellular reactive oxygen species (ROS) as a secondary messenger in 
RANKL-mediated osteoclastogenesis (Kim et al., 2010; Lee et al., 2005; Lee & 
Jang, 2015; Moon et al., 2011). While there has been consensus in the signaling 
cascade set off by RANKL that leads to activation of the Nox1 enzyme 
responsible for the intracellular ROS production, Lee et al. (2005) 
demonstrated that this increase in intracellular ROS occurs in the acute time 
frame following RANKL stimulation and lies upstream of MAPK activation. On 
the contrary, the results of our study are aligned with that of M. S. Kim et al. 
(2010), which showed that the chronic ROS production mediates calcineurin 
activation via calcium oscillations. While ICT suppressed NFATc1 mRNA and 
protein expressions, we show that ICT, by suppressing the superoxide-
generating enzyme Nox1, inhibited ROS production and subsequent 
calcineurin phosphatase activity to prevent NFATc1 nuclear translocation. 
Indeed, both the reduction in NFATc1 protein levels and inhibition in nuclear 
translocation contributed to a decreased NFATc1 transcriptional activity. 
 
Interestingly, resveratrol, the red wine polyphenol, has also been shown to 
inhibit osteoclastogenesis by attenuating chronic ROS production (He et al., 
2010). However, the mechanism underlying resveratrol’s effects has yet to be 
elucidated. Given the similarities observed, our findings suggest a common 
pathway through which compounds like Resveratrol and ICT inhibits ROS 






5.2.3 Proteasomal degradation of the critical adaptor protein, TRAF6, 
mediates icaritin’s suppression of osteoclastogenesis 
The activation of the membrane receptor RANK by its ligand is a sufficient and 
necessary condition for transformation of monocytes/macrophages to 
functioning bone-resorptive osteoclasts. However, the RANK receptor protein 
lacks intrinsic kinase activity and depends on the recruitment of intermediate 
adapter proteins to activate downstream signaling pathways. Although RANK 
associates with several TRAFs, emerging evidence points to a critical 
regulatory function for the adapter protein TRAF6 in RANKL/RANK mediated 
signaling (Walsh & Choi, 2014). The importance of TRAF6 in bone metabolism 
was demonstrated with TRAF6-deficient mice exhibiting defective 
osteoclastogenesis and severe osteopetrosis (Lomaga et al., 1999; Naito et al., 
1999).  Upon stimulation with RANKL, TRAF6 forms an intermediate complex 
to regulate downstream NFκB, MAPK/AP-1 and ROS signaling (Boudot et al., 
2010; Mizukami et al., 2002; Park et al., 2004). We therefore hypothesized that 
RANKL/RANK/TRAF6 system, the critical apex regulator of 
osteoclastogenesis, might be the mechanism through which ICT exerts its 
pleiotropic effects. Since no changes were observed in serum RANKL levels in 
the ovariectomized rats or RANK expression, we deduced that TRAF6 might be 
the direct target for ICT. Indeed, our cellular and animal studies indicate that 
ICT regulates proteasomal degradation of TRAF6, leading to a reduction in 
TRAF6 protein expression in circulating osteoclast precursors and bone. The 
degradative action of ICT on TRAF6 protein is reminiscent of the manner in 





(Takayanagi et al., 2000). Indeed, the inhibitory effects of ICT on 
osteoclastogenesis were reversed in the presence of the proteasomal inhibitor 
MG 132. We have previously shown that ICT leads to destabilization of ERα 
protein via aryl hydrocarbon receptor (AhR) signaling pathways (Tiong et al., 
2012). Additionally, it has been shown that AhR mediates the expression of 
the transcription factor suppressors of cytokine signaling 2, leading to TRAF6 
lysine48-linked polyubiquitination and proteasome-mediated degradation 
(McBerry et al., 2012). Furthermore, our immunoprecipitation studies 
revealed increased ubiquitination, specifically lysine 48-linked 
polyubiquitination, of TRAF6 in the presence of ICT.  On the other hand, AhR 
has also been shown to be a positive regulator of osteoclastogenesis in vitro 
(Yu et al., 2015) and AhR knockout mice exhibit increased bone mass with 
decreased bone resorption (Iqbal et al., 2013; Izawa et al., 2016). As such, a 
challenge for the future remains to investigate if ICT could mediate 
proteasomal degradation of TRAF6 as a result of being an AhR agonist. Overall, 
our data indicate that ICT leads to proteasomal-mediated degradation of 
TRAF6 to suppress osteoclastogenesis. 
 
Interestingly, the degradative effect of ICT on TRAF6 differs from that of 
estrogen, which sequesters the critical adaptor protein in an ERα-BCAR1 
complex, thereby inhibiting RANKL-induced osteoclast differentiation 
(Robinson et al., 2009). Concurring with previous reports (Galal et al., 2007), 
we show that estradiol led to a reduction in RANK expression in osteoclast 
precursors. This suppressive effect of estradiol on RANK expression could 





Using immunoprecipitation studies, Li et al. (2015) showed that Xanthohumol, 
a prenylflavonoid abundant in hops plants, disrupts the association of RANK 
and TRAF6. Given that Xanthohumol led to a dose-dependent decrease in the 
amount of TRAF6 bound to RANK and not vice versa, our findings suggest a 
possible mechanism by which Xanthohumol could lead to proteasomal 
degradation of TRAF6, thereby disrupting the association of RANK and TRAF6. 
 
5.2.4 Comparison with other flavonoids that inhibit RANKL signaling 
Flavonoids, as natural bioactive molecules, have garnered much interest in 
recent years as alternatives for the treatment of postmenopausal osteoporosis 
(Chiba et al., 2003; Horcajada-Molteni et al., 2000; Morabito et al., 2002). 
Indeed, it has been demonstrated that the soybean isoflavones, genistein and 
dadzein, inhibits NFκB and MAPK activation (Karieb & Fox, 2011; Lee et al., 
2014). Although the suppressive effect of ICT on NFκB- and MAPK/AP-1- 
mediated osteoclastogenesis is similar to that of genistein and dadzein, our 
results suggest a divergence in the underlying mechanism. The inhibitory 
effects of these soybean isoflavones on c-Fos and NFATc1 expressions have 
been shown to be estrogen receptor (ER)- dependent (Karieb & Fox, 2011); in 
contrast, the effects of ICT on osteoclastogenesis cannot be reversed with the 
ER antagonist ICI 182,780, suggesting that effects of ICT are ER-independent. 
Indeed, genistein as a result of its estrogenic activity, has been demonstrated 
to lead to uterine hypertrophy in OVX mice (Ishimi et al., 2000), while we 
showed in our animal study that ICT treatment did not lead to changes in 
uterine weight, circumventing the increased risk of endometrial cancer that 






Quercetin, found in many fruits and vegetables, and Ikarisoside A, a flavonoid 
present in the Epimedium genus of herbs, also inhibits osteoclastogenesis in 
RAW 264.7 cells by suppressing both NFκB and AP-1 transcriptional activity 
(Choi et al., 2010; Wattel et al., 2004).  Xanthohumol, a prenylflavonoid 
abundant in hops has also been shown to inhibit NFκB and Ca2+/NFATc1 
signaling pathways to inhibit osteoclastogenesis. As discussed in the previous 
section, Xanthohumol has also been shown to disrupt the association between 
RANK and TRAF6 (Li et al., 2015). Indeed, our experimental data indicate that 
a singular target, TRAF6, may be the key to understanding the plurality of 
actions that lead to suppression of osteoclastogenesis by these flavonoids. Our 
results further suggest a possible mechanism that by mediating proteasomal 
degradation of TRAF6, the decreased TRAF6 protein expression could disrupt 








Table 5.1 Comparison of effects of ICT and flavonoids on RANKL signaling pathway 
 RANKL signaling pathway 







Genistein ↓ ↓ ↓ NFATc1 
expression  
Yes ↓ expression 
Dadzein ↓ ↓ ↓ NFATc1 
expression 
Yes unknown 
















unknown ↓ TRAF6 
association 
with RANK 
Icaritin ↓ ↓ ↓ NFATc1 
expression and 
activity 




↓ Inhibition; ↔ no effect 
(Choi et al., 2010; Karieb & Fox, 2011; Lee et al., 2014; Li et al., 2015; Tsuji et al., 2009; 






5.3 Beneficial effects of icaritin in the OVX rat model  
 
5.3.1 The OVX rat model and timing of administration of icaritin 
 
Given that our in vitro data shows that ICT inhibits osteoclastogenesis, we 
sought to evaluate the anti-osteoclastogenic effects of ICT in the 
ovariectomized rat as a model for estrogen deficiency-mediated osteoporosis. 
 
Although the ovariectomized rat is a well-employed model for studying 
estrogen deficiency-mediated osteoporosis, there has been no consensus on 
timing of administration of treatments (Hsiao et al., 2013; Li et al., 2015; Peng 
et al., 2013; Wu et al., 2012). Our baseline data indicate the establishment of 
the ovariectomy-induced osteoporotic rat model, as we recapitulated the 
endocrine disruptions (estrous acyclicity, weight gain, drastic decrease in 
serum estrogen levels and uterine atrophy) and osteoporotic phenotype of the 
ovariectomized rats. We opted to begin ICT treatment at 4 weeks’ post-
ovariectomy in order that we can ascertain the estrogen-deficient and mild 
osteoporotic status of rats. Furthermore, our experimental model was 
designed to obtain preclinical data to guide clinical studies that assess the 
effect of ICT on postmenopausal women. It is noteworthy that there was a 
further deterioration in the bone architecture and strength of the vehicle-
treated OVX rats from baseline till 8 weeks’ post OVX, which was accompanied 
by an increase in osteoclast numbers and activity as indicated by serum 
markers of bone resorption. These data suggest that the worsening of 





attributed to the increased osteoclastic activity, supporting the validity of our 
model to assess the anti-osteoclastogenic efficacy of ICT. 
 
5.3.2 Preventing OVX-induced deterioration in bone architecture & 
strength 
With our initial findings that ICT inhibits osteoclast differentiation and activity 
in vitro, we postulated that ICT treatment in OVX rats would inhibit estrogen 
deficiency-induced osteoclastogenesis thereby preventing osteoporosis. 
Indeed, treatment of OVX rats with ICT inhibited the deterioration in bone 
architecture, density and strength in both the femur and lumbar vertebrae. In 
concordance with our in vitro studies, ICT treatment significantly inhibited the 
OVX-induced increase in osteoclast numbers and bone resorption. 
Subcutaneous estradiol valerate treatment, as the positive control (da Paz et 
al., 2001; Takano-Yamamoto & Rodan, 1990), also inhibited osteoclast 
formation and activity in the OVX rats. In contrast, ICT treatment at this dose 
did not lead to an increase in estrogenic activity of the serum nor did it lead to 
uterine hypertrophy. These findings support ICT as an alternative for the 
treatment of estrogen deficiency-mediated osteoporosis. 
 
5.3.3 Ameliorating OVX-induced increase in TRAF6 and NFATc1 
expression  
The prevention of estrogen deficiency-mediated osteoporosis by ICT 
treatment was associated with reduced TRAF6 protein expression in 
Cd11b+/Gr-1-/low osteoclast precursors isolated from OVX rats. Interestingly, 





accompanied by increased TRAF6 protein expressions in the osteoclast 
precursors and tibial bone tissue. While this increase in TRAF6 protein 
expression in the vehicle-treated OVX rats could be accounted for by increased 
serum RANKL levels, the suppressive effect of ICT on TRAF6 expression is 
independent of its effects on RANKL levels. Estradiol treatment, on the 
contrary, led to reductions in serum RANKL levels, further pointing to 
differences in the mechanism of action between ICT and estradiol. 
 
We present novel findings that estrogen deficiency-mediated osteoporosis is 
associated with increased NFATc1 protein expression in osteoclast precursors 
and tibial lysates. Similarly, while the increased NFATc1 expression in the 
vehicle-treated OVX rats could be attributed to the increased serum RANKL 
levels, the suppressive effect of ICT is independent of its effects on RANKL. In 
keeping with our in vitro studies, the decrease in NFATc1 protein expression 
in the Cd11b+/Gr-1-/low osteoclast precursors and tibial lysates suggest that 
ICT treatment inhibited osteoclast differentiation in the OVX rats. 
 
5.3.4 Anabolic effect of ICT in osteoporotic bone  
As previously outlined in the introduction, ICT has been shown to enhance rat 
osteoblast proliferation and differentiation, leading to increased calcium 
deposition and enhanced mRNA expression of osteoblast genes (Huang et al., 
2007). ICT has also been shown to enhance osteogenic differentiation of 
human MSCs to osteoblasts under osteogenic induction conditions while 
inhibiting adipogenic differentiation (Yao et al., 2012). Furthermore, ex-vivo 





showed increased osteogenic differentiation along with suppressed 
adipogenesis (Peng et al., 2013). Nonetheless, using a similar OVX-rat model, 
treatment dose and duration, we show that ICT inhibited estrogen deficiency-
induced osteoclast differentiation and activity by downregulating TRAF6 
expression in the OVX rats.  
 
Although the anabolic effects of ICT was not within the focus of the current 
study, we showed that ICT treatment resulted in an increase in the bone 
formation marker, osteocalcin, suggesting that the bone protective effect of 






5.4 Potential clinical applications 
5.4.1 Inflammatory diseases  
TRAF6, as a crucial signaling molecule, also mediates signaling downstream of 
the Interleukin-1/Toll-like receptor superfamily (Martin & Wesche, 2002; 
O'Neill, 2002). Thus, our findings that ICT downregulates TRAF6 protein 
expression may have implications for the treatment of inflammatory diseases. 
Indeed, TRAF6 inhibitors have been shown to reduce inflammation in models 
of peritonitis and sepsis (Zarzycka et al., 2015). Additionally, the anti-
inflammatory properties of ICT have been demonstrated in models of 
peritonitis as well as in myocardial ischaemia and reperfusion injuries (Lai et 
al., 2013; Zhang et al., 2015). Coupled with our findings that this 
prenylflavonoid promotes proteasomal degradation of TRAF6, suggest that 
ICT may be a promising therapeutic option for dysregulated inflammatory 
responses.  
 
Besides its detection in Lewy Bodies, TRAF6 has also been demonstrated to 
play a role in the development of familial Parkinson’s disease (PD). Zucchelli 
et al. (2010) showed that TRAF6, by mediating atypical ubiquitination of DJ-1, 
facilitates its accumulation into insoluble aggregates, one of the hallmarks of 
PD. Chronic inflammation associated with increased TRAF6 expression and 
enhanced activation of NFκB signaling has also been demonstrated in a mouse 
model of PD (Chung et al., 2013). Furthermore, ICT, by promoting proteasomal 





inflammation and cytokine-induced cell death, thus ICT’s potential in 
modulating Parkin-deficiency-induced PD should be explored. 
 
5.4.2 Treatment of postmenopausal osteoporosis and future work  
The clinical trials reported in the literature that studied the effects of 
Epimedium-derived flavonoids on postmenopausal women used either a 
mixture of flavonoids (Zhang et al., 2007) or a decoction that included other 
types of herbs (Zhu et al., 2012). The novel findings presented in this thesis 
opens new possibilities into the study of ICT and its value for treating 
postmenopausal osteoporosis. There is immense clinical potential for our 
findings and we believe that future work should include bringing this research 
into the clinical phase of development. Given that the clinical safety of 
Epimedium-derived flavonoids has been demonstrated in randomized 
controlled trials (Zhang et al., 2007), the efficacy of ICT in improving the bone 
health of postmenopausal women should be investigated.  
 
Based on our in vivo studies, the efficacious dose of ICT that significantly 
ameliorated estrogen-deficiency mediated osteoporosis in the ovariectomized 
rats was 40 mg/kg/day. Using the guidelines published by the US Food and 
Drug Administration for conversion of animal doses to human equivalent 
doses based on body surface area, we converted this efficacious dose to its 
human equivalent dose (U.S. Food and Drug administration, 2005), which 
works out to be approximately 400 mg of ICT daily, for a 60 kg human. This is 





Phase I clinical study of ICT in advanced breast cancer patients (U.S. National 
Institutes of Health, 2015, NCT01972672).  
 
Subject to funding approval, the following trial is currently in the pipeline and 
has been designed as follows: To prevent investigator bias, the study will be 
conducted as a randomized, double-blinded, placebo-controlled outcome 
study. The primary outcome of the study focuses on determining if ICT 
reduces serum markers of bone resorption (CTx and TRAP5b), and to 
determine if any changes occur in serum markers of bone formation (P1NP 
and osteocalcin). BMD measurements of the femoral neck and lumbar 
vertebrae will also be assessed at baseline and at a minimum of 6 months after 
treatment commences. BMD measurements will be combined with the 
aforementioned serum markers to determine the effect of ICT treatment on 
bone turnover. Although recognized to be safe, laboratory biochemical 
examinations (liver function, renal function and full blood count) will be 
conducted to monitor for adverse events. To prevent findings from being 
confounded by other drugs, subjects who are currently or have been taking 
medications or dietary supplements that affect bone turnover (eg. 
bisphosphonates, hormone replacement therapy) within 3 months of the 
study will be excluded. All participants will receive daily elemental calcium in 
calcium carbonate (500 mg) and vitamin D3 (200 IU) supplementation and 
agree to limit their calcium-containing and soy-containing food intake to a 






5.5 Concluding remarks 
In summary, the findings of this thesis uncover new possibilities into the study 
of prenylflavonoids like ICT and provide the grounds for further exploration of 
ICT in treating postmenopausal osteoporosis. Our in vitro mechanistic study 
revealed that ICT inhibited RANKL-induced activation in both the NFκB and 
MAPK/AP-1 pathways to downregulate NFATc1 expression and suppressed 
its transcriptional activity by inhibiting the TRAF6/cSrc/PI3K pathway. ICT 
treatment prevented ovariectomy-induced osteoclast formation and activity to 
suppress estrogen deficiency-induced bone loss and deterioration in bone 
strength. Crucially, the effects of ICT were associated with decreased TRAF6 
protein expression, which was consistently observed both in vitro and in vivo. 
We further delineated that ICT mediates proteasomal degradation of TRAF6 
by increasing lysine 48-specific polyubiquitination of this critical adaptor 
protein. Not only have Epimedium-derived flavonoids long been used in 
eastern ethnopharmacology for the treatment of menstrual irregularities and 
to improve bone health, ICT has also been shown to exert anabolic effects on 
bone. Furthermore, given our findings that ICT inhibits osteoclastogenesis and 
osteoclast resorption strongly support the potential of ICT for the treatment of 
postmenopausal osteoporosis. The findings of this thesis suggest that 
mechanistically, the pleiotropic effects of prenylflavonoids on inhibiting 
osteoclast differentiation could be coordinated through the degradation of the 
adaptor protein TRAF6, and as such TRAF6 is a promising target for the design 
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